


## Scientific Programme – Overview

Tuesday 6 November		Wednesday 7 November			
Auditorium		Auditorium	Liffey A	Liffey B	
		08.00	<b>Workshop 1</b>	<b>Workshop 2</b>	<b>Workshop 3</b>
		09.45	KRAS Mutated Tumours	New Challenges in Immunotherapy	Imaging
		<i>Coffee Break</i>			
		10.15	<b>Workshop 4</b>	<b>Workshop 5</b>	<b>Workshop 6</b>
		12.00	Challenges in Phase 1	Targeting Cell Death	MEK/ERK Inhibitors
12.00	Lunch	Lunch/Poster Viewing Session 12.00-14.15			
13.10	<b>Opening Ceremony</b>	14.15	<b>Keynote Lecture</b>	Exhibition 09:45 - 16:30	
			Future Anti-Cancer Targets: Put the Carts in Front of the Horses?		
13.15	<b>Michel Clavel Lecture</b>	15.00	<b>Plenary Session 2</b>		
	Harnessing Genetic Dependencies In Cancer Therapy		Proffered Papers		
14.00	<b>Keynote Lecture</b>	16.00			
	Agents targeting the mTOR PI3K-Akt pathway		<i>Coffee Break</i>		
14.45	<i>Coffee Break</i>	16.30	<b>Plenary Session 3</b>		
15.15	<b>Plenary Session 1</b>		Biomarkers for Anti-Tumour Evaluation		
	Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?	18.15			
17.00					
17:00 - 18:30	<b>Welcome Reception</b>				

### Posters

Angiogenesis  
 Animal Models  
 Antimetabolites  
 Apoptosis, Necrosis, Autophagy  
 Cellular Therapies  
 Combinatorial Chemistry, Drug Delivery, Drug Design and Drug Synthesis  
 Cytokines  
 Drug Resistance and Modifiers  
 Drug Screening  
 Gene Therapy and Antisense Approaches  
 Metastasis and Invasion  
 Natural Products and Marine Compounds  
 Proteasome and Protein-Protein Interaction  
 RNA and RNA Based Technologies



**Networking Event**

Posters

- Aurora Kinase
- Bioinformatics
- Clinical Methodology
- Cyclins and CDKs
- Differentiation, DNA Repair and Topoisomerase Inhibitors
- Heat Shock Proteins
- Hormonal Agents
- Met, Ret and Notch
- Monoclonal Antibodies and Targeted Toxins/Nuclides
- mTOR
- Paediatric-Early Drug Development
- PARP
- PI3 Kinase
- Signal Transduction Modulators
- Tubulin-Interacting Agents

Posters

- Biomarkers
- Bioreductive Agents
- New Molecular Targets
- Phase 0, I and II
- Radiation Interactive Agents

## Scientific Programme – Details

### Tuesday 6 November 2012

<b>Opening Ceremony</b>			<b>Auditorium</b>
13:10–13:15	Opening remarks		
	13:00 <i>S. Sleijfer (The Netherlands)</i>	EORTC	
	13:05 <i>J. Doroshow (USA)</i>	NCI	
	13:10 <i>M. Foti (USA)</i>	AACR	
			<b>Auditorium</b>
			Abstract number
13:15–14:00	<b>Michel Clavel Lecture</b> Chair: S. Sleijfer (The Netherlands)		
13:15	Harnessing Genetic Dependencies In Cancer Therapy <i>A. Ashworth (United Kingdom)</i>		1
			<b>Auditorium</b>
			Abstract number
14:00–14:45	<b>Keynote Lecture</b> Chair: R. Stupp (Switzerland)		
14:00	Agents Targeting the mTOR-PI3K-Akt Pathway <i>J. Tabernero (Spain)</i>		2
<b>Plenary Session 1</b>			<b>Auditorium</b>
			Abstract number
15:15–17:00	<b>Changing Landscape of Clinical Trial Design – Small Studies, Large Differences?</b> Chairs: J. Doroshow (USA) and J.C. Soria (France)		
15:15	Randomized Discontinuation Designs in Early Clinical Drug Screening – how to Adapt if the Drug Works too well? The Cabozantinib Experience <i>R. Weitzman (USA)</i>		3
15:40	Response-Adaptive Randomized Early Clinical Trials – can BATTLE and SPYs help in co-development of cancer drugs and diagnostics? <i>E. Rubin (USA)</i>		4
16:05	Incorporating Biomarkers Into Phase 2 Trials – Multiple Options, Multiple Challenges <i>L. Collette (Belgium)</i>		5
16:30	Enrichment Strategies for Patient Selection in Early Oncology Trials – a Missed Opportunity, a Must or a way to Focus on the Wrong Target? <i>J. Soria (France)</i>		6

## Wednesday 7 November 2012

<b>Workshop 1</b>		<b>Auditorium</b>
		Abstract number
08:00–09:45	<b>Treating Kras Mutated Tumours</b> Chairs: G. Powis (USA) and S. Tejpar (Belgium)	
08:00	KRAS the Elephant in the Room of Cancer Therapy: New Approaches <i>G. Powis (USA)</i>	7
08:25	Combination Therapy Approaches for KRAS Mutant Cancers <i>J. Engelman (USA)</i>	8
08:50	Mechanisms of transformation by RAS oncogenes: searching for novel therapeutic approaches <i>J. Downward (United Kingdom)</i>	9
09:15	Discussion	
<b>Workshop 2</b>		<b>Liffey A</b>
		Abstract number
08:00–09:45	<b>New Challenges in Immunotherapy</b> Chairs: A. Hoos (USA) and M. Postow (USA)	
08:00	CTLA-4 Blockade for Melanoma: Past, Present and Future <i>J. Wolchok (USA)</i>	10
08:10	Prognostic Markers of the Immune System – Immune Infiltration Into the Tumour <i>J. Galon (France)</i>	11
08:35	The Ying and Yang of the Tumour Microenvironment <i>E. Wang (USA)</i>	12
09:35	Discussion	
<b>Workshop 3</b>		<b>Liffey B</b>
		Abstract number
08:00–09:45	<b>Imaging</b> Chairs: E.G.E. de Vries (The Netherlands) and R. Wahl (USA)	
08:00	From warehouse to new RECIST criteria? <i>S. Litière (Belgium)</i>	13
08:25	Quantitative Assessments of Tumor Response with FDG PET, PERCIST and Beyond <i>R. Wahl (USA)</i>	14
08:50	Imaging Visualisation of Drug Target and Drug Effect <i>E.G.E. de Vries (The Netherlands)</i>	15
09:15	Discussion	
<b>Workshop 4</b>		<b>Auditorium</b>
		Abstract number
10:15–12:00	<b>Challenges in Phase I</b> Chairs: R. Kurzrock (USA) and J. De Bono (United Kingdom)	
10:15	Is There an Optimal Biological Dose? <i>L. Siu (Canada)</i>	16
10:40	The Challenges of Drug Combination Studies <i>J. De Bono (United Kingdom)</i>	17

11:05	Pursuing Molecular Stratification in Phase I Trials <i>R. Kurzrock (USA)</i>	18
11:30	Discussion	
<b>Workshop 5</b>		<b>Liffey A</b>
		Abstract number
10:15–12:00	<b>Targeting Cell Death</b> Chairs: E.H. Rubin (USA) and S. De Jong (The Netherlands)	
10:15	Targeting Cellular Resistance Against Cisplatin-Induced Apoptosis <i>S. De Jong (The Netherlands)</i>	19
10:40	Direct Targeting of Pro-apoptotic BAX for Cancer Therapy <i>E. Gavathiotis (USA)</i>	20
11:05	Targeting the Epigenome to Induce Tumor Cell Death <i>R. Johnstone (Australia)</i>	21
11:30	Discussion	
<b>Workshop 6</b>		<b>Liffey B</b>
		Abstract number
10:15–12:00	<b>MEK/ERK Inhibitors</b> Chairs: J.S. Weber (USA) and D. Solit (USA)	
10:15	Determinants of RAF Inhibitor Resistance <i>D. Solit (USA)</i>	22
10:40	Clinical Status of RAF/MEK Inhibitors <i>J. Weber (USA)</i>	23
11:05	The Role of KRAS/BRAF Mutations on Response and Resistance to Anti EGFR Therapies in Colorectal Tumors <i>A. Bardelli (Italy)</i>	24
11:30	Discussion	
		<b>Auditorium</b>
		Abstract number
14:15–15:00	<b>Keynote Lecture</b> Chair: M. Foti (USA)	
14:15	Future Anti-Cancer Targets: Put the Carts in Front of the Horses? <i>T. Mak (Canada)</i>	25
<b>Plenary Session 2</b>		<b>Auditorium</b>
		Abstract number
15:00–16:00	<b>Proffered Paper Session</b> Chairs: S. Sleijfer (The Netherlands) and J. Doroshow (USA)	
15:00	Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality? <i>J.A. Williams (USA)</i>	26
15:15	NCI-60 Combination Screening Matrix of Approved Anticancer Drugs <i>S. Holbeck (USA)</i>	27
15:30	A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors <i>D.C. Smith (USA)</i>	28

15:45	A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors <i>U. Lassen (Denmark)</i>	29
-------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

**Plenary Session 3****Auditorium**  
Abstract number

16:30–18:10	<b>Biomarkers for Antitumour Evaluation</b> Chairs: D. Parkinson (USA) and C. Dive (United Kingdom)	
16:30	Phenotypic Signaling Pathway Characterization in Complex Cell Populations for Treatment Selection and Response Assessment <i>D. Parkinson (USA)</i>	30
16:55	Genomic and Mutational Profiling of Tumours to Facilitate Personalised Medicine <i>C. Swanton (United Kingdom)</i>	31
17:20	Circulating Tumour Cells, Utility Beyond Prognosis? <i>C. Dive (United Kingdom)</i>	32
17:45	Circulating Free DNA, Mutation Detection and Predictive Biomarker Potential <i>K. Spindler (Denmark)</i>	33

**Poster Sessions****Angiogenesis**

Poster board		Abstract number
001	Efficacy of VEGFR2 Targeted mAb Therapy in Preclinical Colorectal Cancer Model Resistant to Anti-VEGF mAb Therapy <i>D. Surguladze, J. Malaby, M. Prewett, I. Duignan, M. Rutstein, Y.M. Yao, J.D. Schwartz, B. Pytowski</i>	34
002	Influence of VEGF Polymorphism –634 G/C On VEGF mRNA Expression and Susceptibility to Sporadic Colon Cancer <i>T. Cacev, J. Ponos, S. Kapitanovic</i>	35
003	Improved Inhibition of Tumor Growth by the Novel Monoclonal Antibody VGX-100 Targeting VEGF-C in Combination with VEGF-Receptor Tyrosine Kinase Inhibitors <i>A. Tester, D. Phelan, M. Gerometta, R. Klupacs, M.E. Baldwin</i>	36
004	Expression Profiling of Angiogenic Factors, ECM Proteins and Inflammatory Markers and Their Correlation in Indian Patients with Multiple Myeloma <i>A. Sharma, R. Khan, M. Sharma, L. Kumar</i>	37
005	Characterizing Glioblastoma-derived Endothelial Cells <i>J. Weatherbee, Z. Sheng, R.P. Moser, A.H. Ross</i>	38
006	Changes of Vascular Parameters After Bevacizumab Treatment: DCE micro-CT Correlates with Vessel Architecture Examined by 3-dimensional Multispectral Fluorescence Microscopy <i>W. Scheuer, T. Poeschinger, F. Eisa, M. Dobosz, S. Strobel, A. Renner, T. Weber, R. Brauweiler, W.A. Kalender</i>	39

**Animal Models**

Poster board		Abstract number
008	Advantages of Patient Primary Tumor Models Versus Tumor Cell Line Derived Models for Testing Anticancer Agents <i>C. Liu, W.W. Li, W. Zhou, F. He, R. Zhou, C. Bai, C.P. Xu, S.Y. You, D.W. Tian</i>	41
009	MEDI5117 Administration Confers Specific Inhibitions of IL-6 Related Growth Pathways in Tumor Xenograft Models <i>J. Huang, H. Zhong, Z. Liu, C. Morehouse, S. Breen, T. Chen, B. Higgs, R. Hollingsworth, L. Richman, Y. Yao</i>	42
010	Targeting the PI3K/mTOR Pathway for Sarcoma Treatment: Investigation in Rat Syngeneic Chondrosarcoma Model <i>A. Dutour, D. Jury, D. Restagno, A.V. Decouvelaere, M. Belvin, L. Friedman, J.P. Michot, J.Y. Blay</i>	43
011	Spontaneous Cancer in the Dog: a Superior Translational Model for Cancer Drug Development <i>R. Barthel, B. De Wever</i>	44

012	Next Generation RNAi Mouse Models for Drug Discovery and Toxicology Assessment <i>P. Premsrirut, C. Fellmann, L. Dow, S. Lowe, J. Zuber, G. Hannon</i>	45
013	The JAX PDX Resource: Changing the Course of Clinical Advancement <i>B. Wilkinson, R. Rodriguez, H. Chen, R. Gandour-Edwards, N. Goodwin</i>	46
014	Targeting Ptp4a3 in Colon Tumorigenesis and Cancer Progression <i>M.W. Zimmerman, G.E. Homanics, J.S. Lazo</i>	47
015	Lack of Clinical Efficacy of the Combination of Lenalidomide Plus Docetaxel is Predicted by the Lack of Effect in the Orthotopic PC346C Xenograft Model <i>W.M. van Weerden, H. Meulenbeld, A. Boer, D. Stuurman, A. Aghai, C.M.A. de Ridder, R. de Wit</i>	48
016	Champions TumorGraft Models Represent Oncology Clinical Trial Populations <i>T.H. Hewit, B. Lu, E.M. Bruckheimer</i>	49
017	Establishment and Characterization of a C-Myc Mouse Model of Acute Myeloid Leukemia for Therapeutic Evaluation of Signaling Inhibitors <i>C. Drenberg, S. Zatechka, S. Orwick, J. Berk, S. Baker</i>	50
018	Efficacy of Combined Treatment with Trabectedin and Dacarbazine in a Xenograft Mouse Model of Malignant Melanoma <i>D. Sagan, T. Rothhammer-Hampl, F. Jaschinski, A. Schneider, H. Heinrichs</i>	51
019	Dual Bioluminescence/Fluorescence Imaging of Hollow Fibres in Living Animals <i>N. Papadopoulou, T. Coughlan, P. Collier, A. Ritchie, M. Meakin, P.C. Clarke, S.A. Watson, A.M. Grabowska</i>	52
020	In Vivo Oncology Target Screening Using a Lentiviral Inducible-knockdown shRNA System <i>Y. Yinfei, K. Rajendra, S. Subramaniam, P. King, S. Watson, P. Mallinder, A. Grabowska</i>	53
021	Characterization of NOG Mice Reconstituted with Human Hematopoietic Stem Cells (HSC) or Mature Peripheral Blood Mononuclear Cells (PBMC) <i>C. Mignard, J.F. Mirjolet, H. Kissel, F. Bichat, O. Duchamp</i>	54
022	Patient-derived Xenograft Models Reveal a Subset of Clinically Relevant Squamous Non-Small Cell Lung Cancers That Respond to Targeted EGFR Inhibition <i>A. Cranston, A. Mckenzie, P. Mallinder, A. Reece-Smith, A. Lawrence, D. Fairley, A. Grabowska, M. Page, R. Kumari</i>	55
023	Establishment, Characterization and Evaluation of a Panel of Patient-derived Low Passage Breast Tumor Models <i>M. Wick, T. Vaught, S. Kelly, M. Farley, A. Tolcher, A. Rosenthal, L. Rodriguez, M. Beeram, A. Lang, K. Papadopoulos</i>	56
024	New Models of Resistant Melanoma for Preclinical Assays <i>C. Robichon, J.P. Annereau, B. Gomes, A. Pillon, L. De Vries, D. Cussac, N. Meyer, L. Lamant, A. Kruczynski, N. Guilbaud</i>	57
025	Comparison of Optical Imaging Approaches in 2D and 3D in Disseminated Raji-luc B-cell Lymphoma <i>M. Baugher, J. Castorena, J. Baranski, D. Shaw, D. Leopold, E. Trachet, D. Lister, P. McConville</i>	58
026	Relationship Between Interspecies Variability in the Mononuclear Phagocyte System and Nanoparticle Pharmacokinetics <i>W.P. Caron, J.C. Lay, C. Santos, E.P. Merricks, T.C. Nichols, R.K. Ramanathan, P.A. Gehrig, W.C. Zamboni</i>	59
027	Patient-derived Xenograft (PDX) Models of EML4-ALK-driven Non-small Cell Lung Cancer: Development, Characterization and Clinical Correlation Analysis <i>M. Wick, A. Thangasamy, L. Gamez, J. Brown, R. Chavez, A. Tolcher, A. Patnaik, L. Rodriguez, G. Mangold, K. Papadopoulos</i>	60
028	Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies <i>R. Lemos, S. Kopetz, Z. Jiang, A. Dasari, D. Maru, G. Powis</i>	61
029	Early T-cell Precursor Leukemia Arises After Interleukin 7 Receptor Mutations or Lmo2 Overexpression in Primitive Thymocytes <i>L.M. Treanor, S. Zhou, T. Lu, C.M. Mullighan, B.P. Sorrentino</i>	62

- 030 Prospective Molecular Profiling of Canine Cancers Provides a Comparative Model for Evaluating Personalized Medicine Clinical Trials 63  
*M. Paoloni, C. Webb, C. Mazcko, D. Cherba, E.J. Ehrhart, S. Lana, H. Fehling, C. Kingsley, C. Khanna, J. Trent*

**Antimetabolites**

Poster board

Abstract number

- 031 Novel Thymidylate Synthase Inhibitor NKT-TSI-4a Shows Improved PK Profile and Superior Efficacy Compared to Pemetrexed 64  
*C. Brew, S. Lee, R. Jaladi, L. Cheng, S. Dama, J. Riggs, D. Fry, S. Harrison*
- 032 TAS-114 Enhances S-1 Activity in Vivo When Used in Combination 65  
*T. Yokogawa, T. Wakasa, W. Yano, K. Yoshisue, A. Fujioka, K. Eshima, M. Fukuoka, K. Matsuo, K. Noguchi, T. Utsugi*
- 033 Trifluorothymidine Incorporation into DNA is the Primary Mechanism of Action of TAS-102, and Leads to Markedly Prolonged Survival in a Mouse Model 66  
*N. Tanaka, A. Fujioka, K. Yamamura, T. Suzuki, K. Oguchi, K. Ishida, K. Sakamoto, H. Okabe, K. Matsuo, T. Utsugi*
- 034 In Vitro Characterization of a Novel dUTPase Inhibitor, TAS-114, as a Fluoropyrimidine Enhancer 67  
*W. Yano, T. Yokogawa, M. Fukuoka, H. Miyakoshi, S. Miyahara, H. Ueno, S. Tsukioka, K. Matsuo, K. Noguchi, T. Utsugi*
- 035 TAS-114 in Combination, with Capecitabine-based Chemotherapy May Represent a Novel Therapeutic Strategy 68  
*T. Wakasa, K. Yamamura, S. Tsuji, A. Osada, E. Matsushima, T. Yokogawa, M. Fukuoka, K. Matsuo, K. Noguchi, T. Utsugi*

**Apoptosis, Necrosis, Autophagy**

Poster board

Abstract number

- 036 ABT-199, a Selective Small Molecule Inhibitor of Bcl-2, Exhibits Efficacy in Bcl-2 Dependent Malignancies While Sparing Platelets 69  
*J. Levenson, A. Souers, E. Boghaert, D. Phillips, C. Park, M. Wendt, W. Fairbrother, R. Humerickhouse, A. Roberts, S. Elmore*
- 037 A Selective Small Molecule Inhibitor of Mcl-1 Induces Bak Dependent Apoptosis in Cancer Cell Lines 70  
*D.C. Phillips, Y. Xiao, M. Bruncko, C. Park, H. Zhang, L. Wang, G.S. Sheppard, S.W. Elmore, J. Levenson, A. Souers*
- 038 Tolfenamic Acid Induces Apoptosis and Growth Inhibition in Head and Neck Cancer: Involvement of NAG-1 Expression 71  
*C.H. Kim, Y.W. Koh, H. Hong, J.W. Kim, S.U. Kang, J.W. Chang*
- 039 Enhanced Susceptibility to Apoptotic Induction by Mcl-1 Inhibition Through Synergistic Mechanism of Celecoxib and Betulinic Acid in Breast Cancer 72  
*B.N. Prashanth Kumar, S. Rajput, K. Kumar Dey, P. Ipsita, K. Sen, G. Dey, R. Bharti, S. Parida, A. Parekh, M. Mandal*
- 040 Antitumor Activities and Pharmacodynamic Biomarkers of a Novel and Orally Available Small Molecule IAP Antagonist 73  
*H. Sumi, M. Yabuki, K. Iwai, K. Hashimoto, Y. Kosugi, M. Yoshimatsu, T. Ishikawa, S. Yoshida*
- 041 Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 74  
*D. Soncini, S. Bruzzone, A. Cagnetta, I. Caffà, A. Ballestrero, F. Patrone, M. Cea, A. Nencioni*
- 042 YM155-mediated Inhibition of Survivin Expression Enhances TRAIL-induced Apoptosis in Human Triple-negative Breast Cancer Cells 75  
*M. Pennati, S. Sbarra, M. De Cesare, S.L. Locatelli, C. Carlo-Stella, N. Zaffaroni*
- 043 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas 76  
*H. Hurwitz, H. Piot, J. Strickler, J.M. Sorensen, L. Leopold, J. Brill, D.C. Smith*
- 044 Study of the Mechanism of Diallyl Disulfide (DADS) in Transient G2/M Arrest and Apoptosis in U937 Cell Line 77  
*P. Dasgupta, S. Sengupta*



045	Arginine Decarboxylase Inhibits Human Colorectal Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis <i>X. Wei, Y. Leung</i>	78
046	Un“AbI”ing Anti-estrogen Therapy Resistance in Estrogen Receptor-alpha Positive Breast Cancer <i>K.L. Cook, J.L. Schwartz, C.O.B. Facey, L. Jin, A. Zwart, M. Abu-Azab, A. Warri, R. Clarke</i>	79
047	Rational Targeting of Inhibitor of Apoptosis Proteins (IAPs) for Effective Therapy of Malignant Pleural Mesothelioma <i>N. Crawford, C. Holohan, D.J.J. Waugh, D.B. Longley</i>	80
048	MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells <i>M. Mura, Y. He, C. Colley, A. Thakrar, H. Dattani, T.G. Hopkins, E. Stronach, H. Gabra, S. Ali, S.P. Blagden</i>	81
049	Sorafenib and Its Derivative SC-59 Induces Autophagy in Hepatocellular Carcinoma Through SHP-1 Dependent Inhibition of STAT3 <i>H.L. Chen, W.T. Tai, C.W. Shiau, C.Y. Liu, C.S. Lin, A.L. Cheng, P.J. Chen, K.F. Chen</i>	82
050	Investigation of Post-translational Modifications of c-FLIP <i>J.S. Riley, P.G. Johnston, D.B. Longley</i>	83
051	Dieckol, Isolated From Marine Brown Algae Ecklonia Cava, Induces ROS-mediated Apoptosis of Human Ovarian Cancer Cells Via the Multiple Signaling Pathways <i>J. Ahn, K. Lee, J. Choi</i>	84
052	Characterization of a Potent XIAP and CIAP1 Dual Antagonist in Models of Melanoma and Leukemia <i>N. Thompson, M. Ahn, G. Chessari, K. Hearn, C.N. Johnson, J. Lewis, G. Ward, P. Williams, A. Woolford</i>	85
053	Antitumoral Activity of a New Class of Triazenes <i>N. Lüscher, S. Hönes, M. Grubert, M.E. Scheulen, R.A. Hilger</i>	86
054	Inhibition of Autophagy: a Phase 1 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor, Vorinostat, in Patients with Advanced Solid Tumors <i>D. Mahalingam, M. Mita, J. Sarantopoulos, R. Amaravadi, L. Davis, A. Mita, T. Curiel, S. Nawrocki, J. Carew</i>	87
055	Examining the Contribution of BCL-2 Proteins to Chemoresistance in Prostate Cancer Cells <i>V. Del Gaizo Moore, R.E. Wilson</i>	88
056	The HDAC Inhibitor Vorinostat Down-regulates c-FLIP and Sensitizes Human Non-small Cell Lung Carcinoma Cell Lines to Ionising Radiation <i>K.A.J. McLaughlin, K.M. Prise, P.G. Johnston, D.B. Longley, I. Stasik</i>	89
057	Autophagy-related Proteins Impact Outcomes in Acute Myelogenous Leukemia: Proteomic Analysis and Biological Correlates <i>G. Borthakur, M. Andreeff, N. Zhang, Y. Qiu, V. Ruolo, S. Duvvuri, T. Tsao, M. Konopleva, K. Coombes, S. Kornblau</i>	90
058	TRAIL\Apo2L-Smac\Diablo Fusion Molecule with High Cytotoxic Activity Against Cancer Cells <i>J.S. Pieczykolan, S.D. Pawlak, P.K. Rózga, B. Zerek, A. Pieczykolan, M. Szymanik, U. Szawlowska, A. Jaworski, M. Galazka, K. Wiciejowska</i>	91
059	Novel Chimeric TRAIL-Based Protein Overcomes Resistance to TRAIL-induced Apoptosis in Cancer Cells in Vitro and in Vivo by Activation of Mitochondrial Pathway of Apoptosis Independently of TRAIL <i>J.S. Pieczykolan, S.D. Pawlak, B. Zerek, P.K. Rózga, A. Pieczykolan, M. Szymanik, U. Szawlowska, A. Jaworski, M. Galazka, W. Strozek</i>	92
060	Mapping the Interaction Between FLIP and FADD <i>J. Majkut, C. Holohan, M. Sgobba, D. Haigh, D. Longley</i>	93
061	Induction of Autophagy by Imatinib Sequesters BCR-ABL in Autophagosomes and Reduces BCR-ABL Expression <i>M. Nyhan, B. Elzinga, L. Crowley, T. O'Donovan, N. Orfali, G.C. O'Sullivan, M. Cahill, S.L. McKenna</i>	94
062	Medulloblastoma is Primed for Rapid Apoptosis by Constitutively Active Bax: a Unique Vulnerability Which May Be Exploited for Therapeutic Benefit <i>T. Gershon, A. Crowther, I. Garcia, V. Gama, D. Allard, C.R. Miller, M. Deshmukh</i>	95
063	Enhanced Autophagy – an Effective Treatment for Drug Resistant Cancers <i>T. O'Donovan, S. Rajendran, S. El-Mashed, G.C. O'Sullivan, S.L. McKenna</i>	96

064	Birinapant, a Novel Smac Mimetic, Activates Apoptosis in NF-kappaB-dependent Gynecologic Cancer Cell Lines	97
	<i>A.M. Noonan, J. Chen, M. Herrmann, C.M. Annunziata</i>	
065	Inhibition of Proteasome Activity by a New Tick Recombinant Molecule in Sk-Mel-28 Cancer Cells is Accompanied by p53 Up-regulation and Mitochondrial Dysfunction	98
	<i>K. Luciano Pereira Morais, J.G. Souza, S. Michaela Simons, C. Maria Berra, M.T. Fernandes Pacheco, R. Viola Bosch, D. Augusto Maria, A.M. Chudzinski-Tavassi</i>	
066	Smac Mimetic SM-406 Targets Prostate Cancer Tumor Initiating Cells and Enhances the Antitumor Activity of Docetaxel in Vivo	99
	<i>J. Lu, D. McEachern, H. Sun, L. Bai, S. Wang</i>	
067	Use of a Genome-wide Loss-of-function Screen to Identify Novel Mechanisms of Resistance to TRAIL Induced Apoptosis	100
	<i>L.Y. Dimberg, H. Cabrera, C. Menke, K. Behbakht, C.C. Porter, A.C. Taan, A. Thorburn, H.L. Ford</i>	
068	Smac Mimetic Induces Apoptosis and Synergizes with TRAIL in Inflammatory Breast Cancer Cells in an IAP-Dependent and TNF-a-Independent Mechanism	101
	<i>G.R. Devi, J.L. Allensworth, S.J. Sauer, M.M. Morse, H.K. Lyerly</i>	

### Cellular Therapies

Poster board		Abstract number
069	Autoimmune Regulator (Aire) is a Transcriptional Link Between Autoimmunity and Thymus Cancer	102
	<i>E. Oliveira, C. Macedo, C. Collares, E. Sakamoto-Hojo, E. Donadi, G. Passos</i>	
070	Generation and Characterisation of Neratinib-resistant Breast Cancer Cell Line Variants	103
	<i>S. Breslin, S. Rani, C. Corcoran, K. O'Brien, L. O'Driscoll</i>	
071	MAGE-A3 Counteracts Cell Survival in Human Bladder Cancer Cell Lines	104
	<i>J. Hünze, G. Zhou, M. Henrici, A. Hegele, R. Blaheta, R. Hofmann, P. Olbert</i>	
072	Functional Profiling of Clear Cell Ovarian Cancer	105
	<i>R. Miller, R. Brough, I. Bajrami, S. Kaye, S. Banerjee, C. Lord, A. Ashworth</i>	
073	Identifying KRAS New Synthetic Lethality Relationships in Cancer	106
	<i>S. Carvalho, M. Aarts, J. Riffell, C. Torrance, C.J. Lord, A. Ashworth</i>	
074	Multi-level Gene Expression Regulation Effects of the NAMPT Inhibitor FK866 in a Model of Acute T Cell Leukemia	107
	<i>C. Zucal, V.D'Agostino, T. Tebaldi, G. Sociali, S. Bruzzone, A. Quattrone, A. Nencioni, A. Provenzani</i>	
075	Parallel siRNA and Compound Screens to Identify Molecular Determinants of Sensitivity to WEE1 Inhibition in Breast Cancer	108
	<i>M. Aarts, I. Garcia-Murillas, C. Toniatti, A. Ashworth, N.C. Turner</i>	
076	Valproic Acid Downmodulates HDAC3 Expression in Human Glioblastoma Cells	109
	<i>H. Engelhard, Y. Lu</i>	

### Combinatorial Chemistry, Drug Delivery, Drug Design and Drug Synthesis

Poster board		Abstract number
077	Environmental Tobacco Smoke as a Risk Factor to Increasing Respiratory Childhood Infection and Pneumonia in South-West region Nigeria	110
	<i>S. Omiyefa, R. Osoba</i>	
078	Systemic siRNA Delivery with Ultra-Nanoparticles Suppressed Tumor Growth in a Solid Tumor Model	111
	<i>X. Wu, H. Yamamoto, M. Uemura, N. Haraguchi, T. Hata, J. Nishimura, I. Takemasa, T. Mizushima, Y. Doki, M. Mori</i>	
079	Hyaluronic Acid Based Cisplatin Nanogel Selectively Inhibits Growth and Metastasis of Non-Small Cell Lung Cancer, Which Overexpresses CD44	112
	<i>Y.H. Quan, Y.J. Oh, J.H. Park, Y.H. Choi, H.K. Kim</i>	
080	Device for Treatment of Brain Tumor Associated Edema	113
	<i>Q. Ong, F.H. Hochberg, M.J. Cima</i>	
081	A Clinical Drug-drug Interaction Study Between LY2603618, an Inhibitor of Checkpoint Kinase One, and Desipramine, a CYP2D6 Substrate, Conducted in Patients with Advanced or Metastatic Cancer	114
	<i>S.M. Hynes, W. Zhang, J.C. Chandler, E.R. Wickremsinhe, R.L. Decker, P.A. Welch, M.I. Mitchell</i>	

082	Reversal of Drug Resistance to Chlorambucil by Its Conjugation to a Targeting Peptide <i>M. Firer, G. Luboshits, S. Baskin, G. Gellerman</i>	115
083	Transport of the Anticancer Agent, Dp44mT, via a Receptor-mediated Process <i>A.M. Merlot, D.S. Kalinowski, N. Pantarat, S. Menezes, M. Doddareddy, D. Hibbs, D.R. Richardson</i>	116
084	Exploring Novel Temozolomide Analogues to Overcome Glioblastoma Resistance <i>A. Ross, Y.P. Ramirez, R.M. Phillips, R.T. Wheelhouse</i>	117
085	2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek2 <i>B. Carbain, R. Bayliss, K. Boxall, C. Coxon, H. Lebraud, C. Matheson, D. Turner, L. Zhen-Wang, R.J. Griffin</i>	118
086	Effect of Ketoconazole Coadministration On Lenvatinib (E7080) Exposure in Healthy Volunteers <i>R. Shumaker, J. Aluri, J. Fan, G. Martinez, G.A. Thompson, M. Ren</i>	119
087	A Novel Combinatorial Treatment for Glioblastoma of Temozolomide and JLK1486 <i>J. Weatherbee, Y.P. Ramirez, J.L. Kraus, R.P. Moser, A.H. Ross</i>	120
088	Tumor-targeted Nanobullets for Anti-cancer Combination Therapy <i>R. van der Meel, S. Oliveira, I. Altintas, R. Haselberg, R.C. Roovers, P.M.P. van Bergen en Henegouwen, W.E. Hennink, W.E. Storm, R.M. Schiffelers, R.J. Kok</i>	121
089	Drug-loaded Magnetically-responsive Nanoparticles: Validation of Anti-tumor Activity <i>J. Klostergaard, E. Auzenne, C. Seeney</i>	122
090	The Discovery of Potent and Selective Inhibitors of CYP17 Lyase <i>A. Balog, L. Jayaraman, A. Fura, G.D. Vite, M. Gottardis, A. Huang, J.A. Newitt, T.E. Spires, M.T. Obermeier, S.M. Beyer</i>	123

### Cytokines

Poster board		Abstract number
091	Designer Hyper Interleukin 11 (H11) is a Molecule of Great Potential for Treatment of Thrombocytopenia <i>H. Dams-Kozłowska, E. Kwiatkowska-Borowczyk, K. Gryska, A. Mackiewicz</i>	124
092	Screening of Novel Mitotic Kinesin Eg5 Inhibitors in Human Cancer Cells <i>M. Watanabe, M. Serizawa, J. Suzuki, N. Ogo, N. Yamamoto, Y. Koh</i>	125
093	Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC) <i>G. Song, S. Moore, T. Tarrant, M. Dobrovolskaia, D. Barrow, P. Kumar, S. Newman, V. Bae-Jump, P. Gehrig, W. Zamboni</i>	126
094	Tenfold Reduction of the Therapeutic Dose of Tumor Necrosis Factor Through Combination with Alpha-galactosylceramide <i>P. Brouckaert, L. Huyghe, J. Hostens, D. Elewaut</i>	127

### Drug Resistance and Modifiers

Poster board		Abstract number
095	Genetic Expression Alterations in Doxorubicin Resistant MCF7 Breast Cancer Cell-Line <i>M. Zihlif, S.M. AbuHammad</i>	128
096	Activation of the p53 Pathway by RG7112 Enhances Antitumor Effect of Androgen Deprivation and Docetaxel in Prostate Cancer Cells in Vivo <i>B. Higgins, K. Kolinsky, Z. Filipovic, T. Tovar, Y. Zhang, K. Packman, L. Vassilev</i>	129
097	Tanshinone IIA Down-regulates Heat Shock Protein 27 in Pancreatic Cancer Cells and Enhances the Cytotoxic Effect of Gemcitabine <i>Y. Kuramitsu, S. Suenaga, B. Baron, Y. Wang, K. Nakamura</i>	130
098	Suppression of the Growth of Gefitinib-resistant Human Lung Cancer Cells by Indolizino[6,7-b]indole Derivatives <i>T. Lee, C.W. Chen, S. Tala, T.L. Su</i>	131
099	Epithelial to Mesenchymal Transition Leads to Crizotinib-resistance in H2228 Lung Cancer Cells with EML4-ALK Translocation <i>J.C. Lee, H.R. Kim, J.K. Rho, C.M. Choi, S.H. Jang, Y. Hong</i>	132
100	Rac1-related Signaling Pathways Contributing to Head and Neck Carcinoma Radioresistance <i>I. Skvortsova, S. Skvortsov, C.R. Jimenez, J.C. Knol, J. Dudas, P. Eichberger, B. Schiestl, P. Lukas</i>	133

- 101 HDM2 Inhibition Augments the Antitumor and Antiangiogenic Effects of VEGF-R Antagonists by Suppressing SDF-1 Expression and Tumor Recruitment of CD11b/GR1+ MDSC in RCC and Melanoma Xenografts 134  
*D.J. Panka, R.S. Bhatt, J.W. Mier*
- 102 The Role of a Novel MicroRNA Cluster, C19MC, in Breast Cancer 135  
*A. Ward, A. Balwierz, C. Quack, S. Wiemann, O. Sahin*
- 103 Identification and Characterization of BRAF Inhibitors That Inhibit Vemurafenib-Resistant P61BRAFV600E 136  
*S.H. Cheung, R. Du, Y. Zhao, R. Hao, G.L. Zhang, S.H. Wang, M. Wei, C.Y. Zhou, L.S. Luo*
- 104 Haploid Genetic Screens to Identify Determinants of Drug Toxicity and Resistance 137  
*S.J. Pettitt, F. Rehman, R. Brough, C.J. Lord, A. Ashworth*
- 105 The MDM2 Inhibitor Nutlin-3 But Not the p53 Activator RITA Induces Loss-of-function p53 Mutations 138  
*M. Michaelis, F. Rothweiler, S. Barth, J. Cinatl, M. van Rikxoort, A. von Deimling, F. Rödel, D. Speidel, J. Cinatl Jr.*
- 106 Histone Demethylase Inhibitor Overcomes Bortezomib Resistance in Myeloma Cells 139  
*Y. Terui, R. Kuniyoshi, A. Tomida, K. Hatake*
- 107 Unraveling BRAF Inhibitor (PLX4032) Resistance Mechanisms 140  
*A. Azimi, C. Hertzman Johansson, M. Pernemalm, R. Touminen, J. Lehtiö, J. Hansson, S. Egyhazi*
- 108 MM-121, an Anti-ErbB3 Antibody, Inhibits PI3K/AKT Signaling and Viability in Platinum-resistant Ovarian Cells and in Primary Ascites Derived From Chemo-resistant Ovarian Cancer Patients 141  
*M. Curley, A. Kalra, A. Fulgham, D. Xiao, J. Allen, M. Wainszelbaum, G. Garcia, W. Kubasek, G. MacBeath*
- 109 TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models 142  
*K. Miyadera, M. Kato, I. Takahashi, K. Ito, Y. Aoyagi, K. Fukasawa, T. Sagara, K. Yonekura, Y. Iwasawa, T. Utsugi*
- 110 MicroRNA-224 and -375 in Trastuzumab and Lapatinib Acquired and Innate Resistant HER2 Positive Breast Cancer Cells 143  
*K. Howe, A.J. Eustace, S. Souahli, B.C. Browne, S. Aherne, N. Barron, N. Walsh, J. Crown, N. O'Donovan*
- 111 Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive Breast Cancer 144  
*A.J. Eustace, B.C. Browne, M. McDermott, P. O'Leary, L. O'Driscoll, N. O'Brien, L. Gallagher, W. Watson, J. Crown, N. O'Donovan*
- 112 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer 145  
*M.S. McDermott, B.C. Browne, N.A. O'Brien, D.J. Slamon, M. Henry, P. Meleady, M. Clynes, P. Dowling, J. Crown, N. O'Donovan*
- 113 Identification of Tyrosine Kinase Inhibitors as Modulators of OCT2 Function 146  
*J.A. Sprowl, W. Lin, G. Du, R.A. Ness, S.D. Baker, T. Chen, A. Sparreboom*
- 114 Targeting Mechanism of Cell Fusion as a Novel Approach to Abrogate Multi-Drug Resistance of Metastatic Colon Cancer 147  
*D. Cavallaro, S. Capaccioli, V. Carloni*
- 115 Establishment of PI3K Inhibitor-resistant Cancer Cell Lines and the Therapeutic Strategies for Overcoming the Acquired Resistance 148  
*S. Isoyama, S. Dan, Y. Nishimura, G. Kajiwara, N. Nakamura, T. Irimura, T. Yamori*
- 116 Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models 149  
*R. Corcoran, K. Cheng, A. Hata, A. Faber, A. Singh, J. Settleman, C. Benes, M. Mino-Kenudson, K. Wong, J. Engelman*
- 117 Autophagy is a Survival Mechanism Mediating Resistance to Androgen Receptor Signaling Inhibitors in Castrate Resistant Prostate Cancer Cells 150  
*H. Nguyen, J. Yang, H.J. Kung, A. Gao, C. Evans*
- 118 Andrographolide Induces Cell Cycle Arrest in THP-1 Cancer Cell Line and Inhibits Glutathione S-transferase Enzyme Directly 151  
*R. Raghavan, S. Cheriyaundath, J. Madassery*

119	Molecular Mechanisms and Cell Death Pathways in Targeted Therapy-Resistant Breast Cancer <i>R. Montaser, H.M. Coley, T.M. Crook, G.A. Ajabnoor</i>	152
120	Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer <i>S. Kim, T.m. Kim, S.h. Lee, B. Keam, D.w. Kim, D.s. Heo</i>	153
121	Overcoming Acquired Resistance to Afatinib in HCC827, a Non-small Cell Lung Cancer Cell Line <i>J. Hsu, W. Lin, T. Lien, W. Chang, M. Sun, S. Jiang, K. Yen, Y. Chao</i>	154
122	Sorafenib Synergizes with the Antidiabetic Drug Metformin in Non-Small Cell Lung Cancer (NSCLC) <i>F.H. Groenendijk, W.W. Mellema, M.M. Van Den Heuvel, E.F. Smit, R.L. Beijersbergen, R. Bernards</i>	155
123	Aldehyde Dehydrogenase 1A1 Mediates Resistance to Temozolomide in Glioblastoma <i>A. Schaefer, J. Teufel, F. Ringel, J. Schlegel</i>	156
124	Blockage of Nrf2/AKR1C Axis Enhanced Therapeutic Efficacy of Oxaliplatin in Oxaliplatin Resistant Gastric Cancer Cells <i>C. Kuo, C. Chu, C. Huang, J. Chang, W. Pan, L. Chen</i>	157
125	Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action <i>B.Y. Lee, F. Hochgräfe, H.M. Lin, L. Castillo, M. Raftery, L.G. Horvath, R.J. Daly</i>	158
126	Loss of SIRT2 Confers Resistance to Targeted Therapies <i>P. Bajpe, A. Prahallad, P. Halonen, H. Horlings, G. Hooijer, R. Beijersbergen, R. Bernards</i>	159
127	Ku70 Acetylation as a Determinant of Chemosensitivity in Colorectal Cancer <i>C. Holohan, P.G. Johnston, D.B. Longley</i>	160
128	Investigation of Resistance to BRAF Inhibitors in Colon Cancer: Mutation and Chemosensitivity Profiling of 20 Human Colon Cancer Cell Lines <i>G. Kelter, R. Krumbach, T. Giesemann, V. Vuoroqueaux, F. Foucault, T. Metz, T. Metcalfe, H.H. Fiebig</i>	161
129	Resistance to RAF Inhibitors Due to RAS-independent Dimerization of BRAF(V600E) Splicing Variants <i>P.I. Poulidakos, Y. Persaud, M. Janakiraman, M.T. Gabay, K.B. Dahlman, J.A. Sosman, A. Ribas, R.S. Lo, N. Rosen, D.B. Solit</i>	162
130	Functional Screens to Identify Mechanisms of Resistance to FGFR Inhibitors in FGFR Amplified and Mutated Cell Lines <i>M. Herrera Abreu, I. Garcia-Murilla, A. Pearson, S. Shnyder, M. Knowles, N.C. Turner</i>	163
131	The Dual ALK/EGFR Inhibitor AP26113 Also Potently Inhibits Activated and Gatekeeper Mutant Forms of ROS1 <i>R. Anjum, S. Zhang, R. Squillace, T. Clackson, A.P. Garner, V.M. Rivera</i>	164
132	RNAi Screen Identifies ATM-directed Metabolic Pathway as Synthetic Lethal with FLT3 Inhibition in AML <i>M.A. Gregory, A.C. Tan, J. Kim, J. DeGregori</i>	165
133	Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells <i>S. Hobor, S. Misale, E. Crowley, E. Scala, C. Zanon, F. Di Nicolantonio, A. Bardelli</i>	166
134	In Vivo Generation of EGFRi Resistance in a Proprietary Patient-derived Xenograft with an Activating EGFR Mutation (L858R); Subsequent Validation in an Orthotopic Lung Model with 3D Optical Tomographic MicroCT Imaging <i>A. McKenzie, A. Cranston, P. Mallinder, N. Papadopoulou, A. Reece-Smith, D. Onion, A. Grabowska, M. Page, R. Kumari</i>	167
135	Synergistic Anticancer Activity in Vitro and in Vivo of Vorinostat Plus 5-FU/CDDP Via Inhibition of EGFR Activity and Increase of CDDP Intracellular Amount and Platinated-DNA Level <i>A. Budillon, G. Piro, E. Di Gennaro, C. Carbone, M.S. Roca, C. Criscitiello, M.G. Volpe, M. Nazzaro, F. Bruzzese, C. Arra</i>	168

- 136 Combination of Selective ALK Inhibitor ASP3026 with Inhibition of IGF-1R Signaling Overcomes Crizotinib Resistance in NCI-H2228 Human NSCLC Cells 169  
*Y. Ueno, M. Mori, I. Shimada, Y. Kondoh, S. Konagai, H. Sakagami, R. Saito, Y. Kamiyama, R. Elizabeth, S. Kuromitsu*

## Drug Screening

### Poster board

### Abstract number

- 137 A High-throughput Capable Method to Identify Allosteric Inhibitors of Protein Kinase Activation Cascades 170  
*D. Müller, F. Totzke, C. Beisenherz-Huss, C. Heidemann-Dinger, C. Ketterer, D. Krämer, T. Weber, H.G. Kubbutat*
- 138 Chemical-genetic Screens for Synthetic Lethal Interactions in Pancreatic Ductal Adenocarcinomas 171  
*I. Caffa, D. Soncini, F. Ansaldi, A. Provenzani, I. Castiglioni, F. Patrone, A. Ballestrero, A. Nencioni*
- 139 Identification of Small Molecule Inhibitors of Wnt Secretion 172  
*Z. Ke, S. Lim, S. Wang, J. Fulwood, K. Proffitt, B. Madan, M. Choong, H. Flotow, D. Virshup, M. Lee*
- 140 Analysis of Cellular Kinase Activity of Resistance-related EGFR Mutants Using Transmembrane-Domain (TMD) Activated Kinase Variants 173  
*H. Weber, D. Müller, F. Totzke, M. Müller, O. Siedentopf, M.H.G. Kubbutat, R. Graeser, D. Feger, C. Schaechtele, J.E. Ehlert*
- 141 A Standardized Drug-testing Platform Using Human Primary Tumor Samples 174  
*O. Engelking, O. Piloto, L. Doiron*
- 142 Identification of Inhibitors with Specificity for Breast Cancer Cells with Acquired Resistance to Endocrine Treatment 175  
*H. Aguilar, P. Halonen, J. Serra-Musach, A. Rodriguez-Vida, O.M. Tirado, R.L. Beijersbergen, A. Urruticoechea, M.A. Pujana*
- 143 BPR1J271, a Novel FLT3 Inhibitor for Treating Acute Myeloid Leukemia 176  
*C.T. Chen, W.H. Lin, L.H. Chou, C.P. Chen, S.C. Yen, Y.L. Huang, T.K. Yeh, J.T.A. Hsu, W.T. Jiaang, Y.S. Chao*
- 144 A New Fluorescence-based Cell Assay for Visualizing the Wnt Signaling Pathway 177  
*J. Apfel, P. Reischmann, N. v.d. Weiden, O. Müller*
- 145 In Vitro Potency, Selectivity and Inhibitory Activity of a Novel FLT3 Inhibitor 178  
*J. Hsu, W. Lin, W. Jiaang, K. Yen, S. Hsieh, S. Yen, K. Chang, Y. Huang, Y. Chao, C. Chen*
- 146 Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS 179  
*F. Becker, M. Borgmann, J. Bertram, K. Hansen, M. Koch, S. Hannus*
- 147 Primary Human Xenografts Provide More Accurate Clinical Information Compared to Cell Line Xenografts in Vivo Chemosensitivity Testing 180  
*G. Sadadcharam, M. McCourt, D.G. Power, S. O'Reilly, J.H. Wang, H.P. Redmond, E.J. Andrews*
- 148 Direct Visualizing of the Activity of the Ras/Raf Pathway by Fluorescent Cell Assays 181  
*P. Reischmann, J. Apfel, O. Müller*
- 149 Three-dimensional, Humanised Tumour Growth Assays with Low Passage Tumours Provide a Patient-relevant Screen for Novel Chemotherapeutics 182  
*D. Onion, R. Argent, A. Reece-Smith, A. McKenzie, R. Kumari, B. Hall, P. King, S. Watson, A. Grabowska*
- 150 Antitumor Potential of Ig Complementarity-determining Region Derived Peptides Against Experimental Melanoma 183  
*C.R. Figueiredo, A.L. Matsuo, C.F. Farias, M.H. Massaoka, J.A.B. Scutti, A.N. Rabaça, N. Girola, R.A. Azevedo, L.R. Travassos*
- 151 Casoparan Casein Derived Peptide Induces Cell Cycle Arrest and Confers Antimetastatic Protection in a Melanoma Model 184  
*R.A. Azevedo, A.L. Matsuo, C.R. Figueiredo, M.H. Massaoka, A.V.V. Auada, A.K. Ferreira, R. Marques-Porto, K.C. Pasqualoto, L.R. Travassos, I. Lebrun*
- 152 ICL-CCIC-0019, a Novel and Selective Inhibitor of Choline Kinase Alpha with Significant Antitumor Activity 185  
*S. Trousil, M. Kaliszczak, L. Carroll, E.O. Aboagye*

153	Mechanistic Differences Between a New Platinum(II) Mono-sulphonamide and Cisplatin in Melanoma Cell Lines <i>A. Agudo-López, C. Perez, C.V. Diaz-Garcia, V. del Solar, J. Aleman, M.T. Agullo-Ortuño, H. Cortes-Funes, C. Navarro-Ranninger, J.A. Lopez-Martin</i>	186
154	Bioluminescent Assays to Monitor NAD(P)/NAD(P)H Levels and Reactive Oxygen Species in Live Cells <i>R. Somberg, S. Duellman, J. Vidugiriene, W. Zhou, D. Leippe, H. Wang, J. Schultz, P. Meisenheimer, J. Cali, H. Wang</i>	187
155	NanoLuc: a Smaller, Brighter, and More Versatile Luciferase Reporter <i>K. Kopish, M. Hall, B. Binkowski, M. Valley, B. Butler, T. Machleidt, M. Robers, C. Eggers, L. Encell, K.V. Wood</i>	188
156	Establishment, Characterization and in Vivo Evaluation of Preclinical Tumor Models to Elucidate Differential Response to EGFR-targeted Therapies <i>M. Wick, T. Vaught, A. Thangasamy, J. Meade, A. Tolcher, A. Patnaik, L. Smith, R. Drengler, A.J. White, K. Papadopoulos</i>	189
157	Patient-derived Tumor Xenografts in Combination with High Content Imaging Platform as Models for Oncology Drug Development <i>K. Praveen, N. Streiner, T. Ruiz-Lorroya, M. Garg, B. Murali, S. Hoffmaster, M. Vo, T. Broudy, C. Mirsaidi</i>	190

### Gene Therapy and Antisense Approaches

		Abstract number
Poster board		
158	Combining siRNAs Targeting Thymidylate Synthase and Thymidine Kinase 1 or 2 Sensitizes Human Tumor Cells to the Anticancer Drugs 5FUdR, Pemetrexed and Gemcitabine <i>C. Di Cresce, R. Figueredo, P.J. Ferguson, M.D. Vincent, J. Koropatnick</i>	191
159	Enhancement of Cisplatin Cytotoxicity by Antisense Oligonucleotides Targeting DNA Repair Protein BRCA2: Creation of Synthetic Lethality to Improve Selectivity <i>P.J. Ferguson, M.D. Vincent, R. Figueredo, M. Rytelowski, J. Koropatnick</i>	192
160	Generation of Novel Reporter Cell Lines Facilitating the Measurement of Endogenous Gene Expression <i>S. Grooby, H.M. Astley, J. Elliott, T. Henley, K.M. Pytel, A. Smith, S. Griffin, A.S. Little, R.E. Foster, K.M. Grimshaw</i>	193
161	In Vitro Evaluation of Cytotoxic Potential of Alphaviral Vectors in Combination with Chemotherapeutic Agent for Cancer Treatment <i>A. Zajakina, J. Vasilevska, A. Spaks, T. Kozlouska</i>	194
162	Intramuscular Electroporation of an Optimized RheoSwitch <sup>®</sup> -regulated Interferon Alpha Plasmid Transgene Shows Long Term Persistence in Vivo: Implications for Therapy of Cancer <i>P. Agarwal, T. Chan, J. Roeth, C. Reed, Z. Yang, J.A. Barrett, F. Khazi, H. Youssoufian, R. Herberman, W.E. Fogler</i>	195
163	Characterization of Generation 2.5 Androgen Receptor Antisense Oligonucleotides Targeting Full Length AR and AR Splice Variants <i>T. Zhou, Y. Kim, B.P. Monia, Y. Yamamoto, B. Eliana, M. Gleave, A.R. MacLeod</i>	196
164	Malignant Cell Specific Nanotherapeutic Targeting of CK2 <i>K. Ahmed, G.M. Unger, J.J. Wu, D.K. Tobolt, V.L. Korman, J.W. Slaton, B.T. Kren, J.H. Trembley</i>	197

### Metastasis and Invasion

		Abstract number
Poster board		
165	Antitumor Effect of Chk1 Inhibitor LY2603618 in Combination with Gemcitabine in SW1990 Pancreas Orthotopic Tumor Model <i>W. Wu, C. Bi, R. Beckmann, R. Foreman, T. Wang, A. Bence</i>	198
166	Novel Functions of Cyclin A2 in Epithelial-Mesenchymal Transition and Metastasis <i>C.T. Cheung, N. Bendris, H.S. Leong, J.D. Lewis, A.F. Chambers, J.M. Blanchard, B. Lemmers</i>	199
167	Suppression of Tumor Growth and Metastasis by Anti-Podoplanin Antibodies <i>A. Kunita, M.K. Kaneko, S. Abe, M. Fukayama, Y. Nishioka, Y. Kato</i>	200

- 168 Combinatorial Effect of ZD6474 and Thymoquinone Inhibits Src Mediated ERK-1/2/STAT3 Signalling and Renders Antimetastasis in Breast Cancer 201  
*S. Rajput, K. Kumar Dey, P. Ipsita, K. Sen, G. Dey, R. Bharti, S. Parida, A. Parekh, M. Mandal*
- 169 Involvement of Cysteinyl Leukotriene Receptor 1 (CysLT1) in Second Wave Rac1 Activation in the Process of EGF-induced Cell Migration 202  
*S. Magi, Y. Takemoto, H. Kobayashi, E. Tashiro, M. Imoto*
- 170 The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Prevents Hypoxia-induced Epithelial to Mesenchymal Transition Through Interfering the Expression of Hif-1alpha 203  
*L. Zhang, J. Cao, G.Y. Lin, Y.Z. Hu, B. Yang, Q.J. He*
- 171 Modulation of Tumour Cell Migration by Inhibition of Polysialic Acid Biosynthesis 204  
*B.R. Springett, Y.M.J. Al-Saraireh, M. Sutherland, L.H. Patterson, S.D. Shnyder, R.A. Falconer*
- 172 Development of Metastasis Following Inhibition of VEGFR Pathway in an Orthotopic Neuroblastoma Model 205  
*E. Daudigeos-Dubus, L. Le Dret, C. Philippe, F. Andreiuolo, O. Bawa, N. Pata-Merci, F. Munier, G. Vassal, B. Georger*
- 173 Expanded Phenotypic and Biological Characterization of Rare Cells Isolated From Prostate, NSCLC and Pancreatic Cancer Patient Blood Using ApoStream™ 206  
*K. Anderes, C. Neal, V. Melnikova, D. Davis*
- 174 Intetumumab, an Anti-pan  $\alpha_v\beta$  Integrin Antibody, Reduces Tumor Burden in an Experimental Model of Established Lung Metastasis 207  
*G. Cheng, Y. Wang, J. Han, J. Jin, M. Guo, Y. Li, P. Doshi, L. Wang, D. Sutton*
- 175 Intetumumab Inhibits TGF $\beta$  Induced EMT and Activates MET by Blocking AV $\beta$  Integrins 208  
*J. Zhang, B. Jiang, Y. Zhang, X. Ma, P. Doshi, D. Sutton, L. Wang*
- 176 Variable Expression of GLIPR1 Correlates with Promoter Methylation and Invasive Potential in Melanoma Cells 209  
*J. Tyndall, A. Awasthi, A.G. Woolley, S.M. Wilbanks, A. Jeffs*
- 177 The Development of Distant Metastases in Postmenopausal Woman with Breast Cancer in Association with VEGF Gene Polymorphisms 210  
*S. Krenn-Pilko, E.M. Thurner, W. Renner, G. Absenger, A. Gerger, K.S. Kapp, T. Langsenlehner, U. Langsenlehner*
- 178 SPON2, a Newly Identified Transcriptional Target Gene of MACC1, is Associated with Colorectal Cancer Metastasis 211  
*F. Schmid, Q. Wang, M. Huska, M. Andrade, I. Fichtner, P.M. Schlag, U. Stein*
- 179 Cadherin-catenin Protein Expression Profile in Ovarian Neoplasms 212  
*S. Amin, N. Al-Mutairi, L. Pelletier, J. Weberpals, S. Islam*
- 180 In Vitro Binding Characteristics of Tc 99m Tilmanocept Translate to Superior Clinical Performance at Varying Injection to Surgery Time Intervals: False Detection Rates and Sensitivities in Breast Cancer and Melanoma Patients 213  
*F.O. Cope, W.L. Metz, R.D. Hartman, M.T. Joy, B.C. Abbruzzese, B.M. Potter, J.L. Shuping, L.A. Christman, D.W. King*
- 181 Androgen Receptor Expression in in Circulating Tumor Cells, Archival and Metastatic Tissue in Prostate Cancer Patients 214  
*K. Anderes, V. Melnikova, M. Pace, S. Sukumaran, M. Garza, B. Redden, J. Woo, D. Davis, R. Amato*
- 182 Circulating Tumor Cells as Surrogate Biomarkers of Epithelial Mesenchymal Transition and Metastatic Phenotype in Prostate Cancer Patients 215  
*R. Amato, V. Melnikova, M. Pace, S. Sukumaran, M. Garza, B. Redden, J. Woo, K. Anderes, D. Davis*

## Natural Products and Marine Compounds

- Poster board Abstract number
- 183 Potent Spliceostatin Analogs Isolated From *Pseudomonas* by Manipulations of Fermentation and Co-Culturing Conditions 216  
*M. He, K. Zuck, S. Shipley, L. Giddings, T. DeLloyd, D. Newman*
- 184 In Vitro Study of Yondelis in Combination with a Panel of PARP Inhibitors 217  
*V. Moneo, G. Santamaria, G. Tarazona, P. Martinez, B. de Castro, S. Cascajares, C. Cuevas, L. Garcia-Fernandez, C.M. Galmarini*
- 185 TC-NER Dependent Degradation of RNA Pol II in Response to Lurbinectedin (PM01183) 218  
*G. Santamaria, J.F. Martinez-Leal, C. Cuevas, L. Garcia-Fernandez, C.M. Galmarini*



186	Inhibition of p53–Mdm2 Interaction by Ellagitannins	219
	<i>D. Tatsuda, Y. Umezawa, M. Iijima, I. Momose, A. Nomoto</i>	
187	Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental Models	220
	<i>R. Frapolli, E. Bello, M. Zangarini, P. Zucchetti, P. Aviles, M. D'Incalci</i>	
188	Lurbinectedin (PM01183) in Combination with Gemcitabine in Patient-Derived, Pancreatic Ductal Adenocarcinoma (PDA) Xenografts	221
	<i>P.P. López-Casas, M. Hidalgo, M.J. Guillén, F. Sarno, O. Cataluña, M. Palomares, C. Cuevas, P. Aviles</i>	
189	Lurbinectedin (PM01183): Pharmacokinetics/Pharmacodynamic (PK/PD) Properties in Pancreas, Ovarian and NSCLC Xenografts	222
	<i>P. Aviles, M.V. Céspedes, M.J. Guillén, P. Alamo, A. Bishop, A. Gallardo, T. Pernice, R. Mangues, C. Cuevas</i>	
190	Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor Xenografts	223
	<i>R. Mangues, M.V. Céspedes, M.J. Guillén, P. Alamo, R. López, A. Gallardo, P. Nuñez, C. Cuevas, P. Aviles</i>	
191	The Relationship Between the Anti-cancer Activity of the Omega-3 Polyunsaturated Fatty Acid Eicosapentaenoic Acid (EPA) and Colorectal Cancer Cell Migration	224
	<i>M. Volpato, L. Coletta, P.M. Loadman, M.A. Hull</i>	

### Proteasome and Protein–Protein Interaction

	Poster board	Abstract number
192	Diversity in Individual Src-family Kinase Regulation: Opportunities for Selective Inhibitor Discovery	225
	<i>J.A. Moroco, J.K. Craigo, N.S. Gray, T.E. Smithgall</i>	
193	ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled A-helical Peptide Exhibits Potent in Vitro and in Vivo Efficacy in Xenograft Models of Human Cancer	226
	<i>Y. Chang, B. Graves, V. Guerlavais, L. Vassilev, K. Packman, K. Olson, A. Annis, C. Tovar, H. Nash, T. Sawyer</i>	
194	Association of K-Ras Genotype with Xenograft Tumor Response to the Investigational Proteasome Inhibitor MLN9708	227
	<i>N. Chattopadhyay, A. DiBacco, J. Garnsey, B. Bannerman, P. Hales, J. Yu, G. Mulligan, E. Koenig, A. Berger, M. Manfredi</i>	
195	Anti-tumor Efficacy with a Novel Peptide Inhibitor of the PD-1 Immune Check Point Pathway	228
	<i>M. Ramachandra, P.G. Sasikumar, L.K. Satyam, R.K. Shrimali, K. Subbarao, R. Ramachandra, S. Vadlamani, A. Reddy, A. Sreenivas, D.S. Samiulla</i>	

### RNA and RNA Based Technologies

	Poster board	Abstract number
196	Alternative Splicing of Kruppel-like Factor 4 Plays a Role in Colorectal Tumorigenesis	229
	<i>S. Baek, J. Bahn, S. Lee, D. Smolensky, J. Yoon</i>	
197	An Entirely Novel Nanoparticle Carrying a Bioactive shRNA Molecule (DFP-10825) Could Be Clinically Effective Against the High Risk Patients with Mesothelioma Relapsed or Refractory After Treatment with Pemetrexed Based Chemotherapy	230
	<i>T. Ishida, A.S. Abu Lila, C. Huang, H. Wada, M. Fukushima, H. Kiwada</i>	
198	A Novel siRNA Screening Approach for Target Identification in Oncology: Focus On Purinome Enzymes	231
	<i>F. Gasparri, A. Carugo, A. Galvani, L.M. Gianellini, M.L. Giorgini, A. Isacchi, R. Lupi, C. Perrera, L. Raddrizzani, R. Colombo</i>	
199	Targeting MicroRNAs to Enhance a Novel Therapy for Glioblastomas	232
	<i>A. Ross, Y.P. Ramirez, R.P. Moser, L.M. Minter</i>	

## Thursday 8 November 2012

### Plenary Session 4

**Auditorium**  
Abstract number

08:00–09:45	<b>Next Generation Gene Sequencing: How to Use?</b> Chairs: S. Friend (USA) and A. Futreal (United Kingdom)	
08:00	Introducing Genomics into Clinical Trials <i>T. Zhang (USA)</i>	233
08:35	Intratumoural Heterogeneity: Roots, Trunks and Branches <i>A. Futreal (United Kingdom)</i>	234
09:10	Integrating Cancer Networks and the Value of Compute Spaces <i>S. Friend (USA)</i>	235

### Plenary Session 5

**Auditorium**  
Abstract number

10:15–12:00	<b>Drug Dosing</b> Chairs: M.J. Ratain (USA) and J. Verweij (The Netherlands)	
10:15	Finding the Right Dose for the Population <i>J. Verweij (The Netherlands)</i>	236
10:45	Understanding and Managing INTER-Individual Pharmacokinetic Variability <i>S. Baker (USA)</i>	237
11:15	Understanding and managing intraindividual pharmacokinetic variability <i>M.J. Ratain (USA)</i>	238

### EORTC/IMI Project Session

**Liffey A**  
Abstract number

12:30–14:00	<b>Reducing Attrition Rates in Anticancer Drug Discovery and Development: IMI Approaches</b> Co-chairs: J. Waterton (United Kingdom) and D. Lacombe (Belgium)	
	Introduction <i>D. Lacombe (Belgium)</i>	
	PREDECT: in vitro models for target validation that may better represent tumor complexity <i>J.A. Hickman (France)</i>	239
	OncoTrack: Methods for Systematic Next Generation Oncology Biomarker Development <i>D. Henderson (Germany)</i>	240

QuIC-ConCePT: Quantitative Imaging in Oncology – Connecting Cellular Processes to Therapy  
*J.C. Waterton (United Kingdom)* 241

**Auditorium**  
 Abstract number

14:15–15:00 **Keynote Lecture**  
 Chair: J. Doroshow (USA)

14:15 Next-Generation Therapeutics for Unconventional Targets 242  
*G.L. Verdine (USA)*

### Plenary Session 6

**Auditorium**  
 Abstract number

15:00–16:00 **Proffered Paper Session**  
 Chairs: P. Schöffski (Belgium) and R. Stupp (Switzerland)

15:00 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors 243  
*R. Bahleda (France)*

15:15 Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC) 244  
*D. Petrylak (USA)*

15:30 Towards Prediction of Efficacy of Chemotherapy: a Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography 245  
*A.A. van der Veldt (The Netherlands)*

15:45 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors 246  
*F. Janku (USA)*

### Plenary Session 7

**Auditorium**  
 Abstract number

16:30–18:15 **Microenvironment**  
 Chairs: T. Gajewski (USA) and N. Harbeck (Germany)

16:30 Contribution of B7-H1 to Immune Suppressive Microenvironment in Cancer 247  
*L. Chen (USA)*

16:55 Targeting Tumour–Stroma Interaction for Prevention of Metastasis 248  
*N. Harbeck (Germany)*

17:20 Innate and adaptive immunity regulated within the tumor microenvironment 249  
*T. Gajewski (USA)*

17:45 Angiogenesis and Immune Modulation 250  
*J. Allison (USA)*

### Poster Sessions

#### Aurora Kinase

Poster board Abstract number

001 Highly Potent and Selective Aurora A Inhibitor, TAS-2104 Enhanced Antitumor Activity of Taxanes in Vitro 251

*H. Sootome, N. Masuko, K. Ishihara, M. Mitsuya, H. Hirai, T. Utsugi*

002 TAS-2104, a Highly Potent and Selective Aurora A Inhibitor, Enhanced Antitumor Activity of Taxanes in Vivo 252

*K. Ishihara, N. Masuko, H. Sootome, T. Suzuki, M. Okada, H. Hirai, T. Utsugi*

003	Anti-tumor Activity of the PLK Inhibitor Volasertib (BI 6727) and the Aurora Kinase Inhibitor BI 811283 in Pediatric Malignancies <i>C. Lanvers-Kaminsky, S. Abbou, E. Daudigeos-Dubus, J. Molenaar, A. Verschuur, H. Caron, G. Vassal, B. Georger</i>	253
004	In Vitro and in Vivo Antitumor Activity of the Investigational Aurora A Selective Kinase Inhibitor MLN8237 Alone and in Combination with Standard Agents Against CRC Models <i>T.M. Pitts, K.L. McPhillips, H.M. Selby, A. Spreafico, S.M. Bagby, B.C. Britt, A.C. Tan, J.J. Tentler, J.A. Ecsedy, S.G. Eckhardt</i>	254
005	Molecular Markers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Human Colorectal Cancer (CRC) Models <i>J. Tentler, S.M. Bagby, A.C. Tan, T.M. Pitts, H.M. Selby, K.L. McPhillips, S.G. Eckhardt, S. Leong</i>	255
006	Mechanism-based Preclinical PK/PD/E Relationships for Alisertib, an Investigational Small-molecule Inhibitor of Aurora A Kinase, in a Range of Human Solid Tumor Xenografts <i>S. Palani, M. Patel, M. Zhang, S. Balani, J. Mettetal, M. Manfredi, K. Venkatakrishnan, J. Ecsedy, W. Shyu, A. Chakravarty</i>	256
007	BRG1-Inactivating Mutations as Potential Predictive Markers for Aurora Kinase A-Targeted Therapy <i>V. Tagal, M.G. Roth, A. Gazdar, J.D. Minna</i>	257

### Bioinformatics

		Abstract number
Poster board		
008	An Integrative Omics Strategy for Identification of Skin Cancer Biomarkers <i>D. Barh, K. Gupta, G. Khatri, S. Rahangdale, A. Verma</i>	258
009	Increasing Insight into Therapeutic Mode of Action: a Novel Application of RNA Seq to Differentiate Tumour and Host Expression Profiles in Human Xenografts <i>J.R. Bradford, M. Farren, S.J. Powell, S. Runswick, S.L. Weston, H. Brown, H. Carr, J.R. Dry, N.J. Gibson, S.T. Barry</i>	259
010	Deformability-based Isolation of Circulating Tumor Cells in Lung Cancer Patients with Microcavity Array System <i>Y. Koh, H. Kenmotsu, M. Hosokawa, T. Yoshino, T. Naito, R. Watanabe, S. Ono, H. Kanbara, T. Matsunaga, N. Yamamoto</i>	260
011	A Fully Automatic Procedure for Image Derived Blood Extraction, Including Assessment of Metabolite, in Dynamic PET Fluorothymidine (FLT) Studies <i>F. O'Sullivan, M. Muzi, J. Huang, J.F. Eary, J. Link, K.A. Krohn</i>	261
012	Overall Survival of BRCA1-associated Breast Cancer is Better Than Predicted by Adjuvant! Online and PREDICT: a Hospital-based Study in Latvia <i>G. Plakhins, A. Irmejs, A. Gardouskis, S. Subatniece, I. Liepniece-Karele, G. Purkalne, U. Teibe, G. Trofimovics, E. Miklasevics, J. Gardouskis</i>	262
013	Validation of Preclinical Colorectal Cancer Models Against TCGA Data for Pathway Analysis and Predictive Biomarker Discovery <i>A. Tan, B. Britt, D. Astling, S. Leong, C. Lieu, J. Tentler, T. Pitts, J. Arcaroli, W. Messersmith, S. Eckhardt</i>	263

### Clinical Methodology

		Abstract number
Poster board		
014	Combined Imaging with 18F-FLT PET/CT and 99m-Tc-Hynic-Annexin V SPECT for Personalized Therapy with EGFR Antagonists and Bcl-xL Inhibitors in Non-Small Cell Lung Cancer <i>A. Zannetti, F. Iommelli, V. De Rosa, A. Nardelli, G. Ortosecco, S. Del Vecchio</i>	264
015	Next Generation Personalized Medicine Strategies Incorporating Genetic Dynamics and Single Cell Heterogeneity May Lead to Improved Outcomes <i>R.A. Beckman, G.S. Schemmann, C.H. Yeang</i>	265
016	A Novel Rapid and Accurate Lung Cancer Diagnostic Method Using Fluorescent Bacteria <i>Y. Zhu, B. Dong</i>	266
017	OncoMap Genotyping of Recurred Non-small Cell Lung Cancer Helps to Differentiate the Second Primary Lung Cancers From the Metastasis Cases <i>S.H. Jang, S.J. Jang, C.M. Choi, J.C. Lee</i>	267

018	CellMiner: a Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set	268
	<i>Y. Pommier, W.C. Reinhold, M. Sunshine, S.H. Varma, K.W. Kohn, J.H. Doroshow</i>	
019	Does the Addition of Molecular Targeted Therapy to Standard Treatments Lead to Better or Worse Outcomes Overall? A Systematic Review and Meta-analysis of EGFR-targeted Therapies Used in Combination with Standard Treatments	269
	<i>J. Rauw, M. Ennis, M. Krzyzanowska, S. Sridhar</i>	
020	The Impact of a Tissue Acquisition Program On Research in Molecular Targeted Therapy of Melanoma	270
	<i>M.C. Kelley, A. Richmond, S. Chase, A. Gecewich, H. Crandall, M.A. Hooks, I. Puzanov, J.A. Sosman</i>	

### Cyclins and CDKs

	Poster board	Abstract number
021	In Vitro Studies of Novel Ruthenium(II) and Osmium(II) Indoloquinoline Complexes	271
	<i>S. Göschl, L.K. Filak, A. Egger, M.A. Jakupec, B.K. Keppler, V.B. Arion</i>	
022	Discovery and Development of Potent CDK9-selective Inhibitors for Cancer Treatment	272
	<i>Z. Gao, J. Sutton, T. Abrams, M. Faure, K. Yu</i>	
023	High-Throughput Screening to Identify Small Molecule Inhibitors of P27 <sup>Kip1</sup> Ubiquitination	273
	<i>N. Watanabe, L.C. Ooi, H. Osada</i>	
024	Synthesis and in Vitro Evaluation of Selective CDK9 Inhibitors	274
	<i>H. Shao, A.Y. Abbas, S. Shi, D. Foley, S. Huang, T.D. Bradshaw, C. Pepper, J.A. Endicott, S. Wang, P.M. Fischer</i>	

### Differentiation, DNA Repair and Topoisomerase Inhibitors

	Poster board	Abstract number
025	Targeting XRCC1 (X-ray Repair Cross-complementing Gene 1), a Key DNA Base Excision Repair Protein for Personalized Therapy in Breast and Ovarian Cancer	275
	<i>R. Sultana, T. Abdel-Fatah, N. Albarakati, R. Abbotts, C. Seedhouse, G. Ball, S. Chan, E. Rakha, I. Ellis, S. Madhusudan</i>	
026	A Small Molecule Inhibitor of the BLM Helicase That Modulates Chromosome Stability in Human Cells	276
	<i>T.S. Dexheimer, G.H. Nguyen, A.S. Rosenthal, V.A. Bohr, C.C. Harris, A. Jadhav, O. Gileadi, D.J. Maloney, A. Simeonov, I.D. Hickson</i>	
027	Single Agent Activity of the Novel Checkpoint 1 Kinase Inhibitor V158411	277
	<i>P. Stephens, A. Massey, R. Plummer, N. Curtin</i>	
028	Chemosensitisation By, and Single Agent Activity of, ATR Inhibitor VE-821 in Human Breast Cancer Cells	278
	<i>F.K. Middleton, T. Chen, J.R. Pollard, N.J. Curtin</i>	
029	Synthesis and Development of Prodrug BCCA621C: a Hypoxia Triggered DNA-PK Inhibitor	279
	<i>K. Lindquist, J. Cran, K. Kordic, G. Winters, P. Chua, J. Tan, A. Kyle, M. Smith, A. Minchinton</i>	
030	Mechanisms of Tumor Targeting with Etirinotecan Pegol (NKTR-102): the Impact of Polymer Conjugation On Tumor Accumulation	280
	<i>D. Fry, J. Zhang, H. Gursahani, U. Hoch, M. Eldon, D. Charych, S. Lee, A. Kozlowski, T. Vinson, C.N. Eid, S. Harrison</i>	
031	Germline Claspin Mutations and Somatic Inactivation in Gliomas	281
	<i>D. Azenha, C. Lopes, T.C. Martins</i>	
032	Downregulation of BRCA2 and Thymidylate Synthase (TS) Sensitizes Human Tumour Cells to Chemotherapy: Induction of ‘Complementary Lethality’ by Targeting DNA Repair	282
	<i>M. Rytelewski, M.D. Vincent, P.J. Ferguson, S. Maleki-Vareki, R. Figueredo, J. Koropatnick</i>	
033	Genetic Variants in the TGF- $\beta$ 1 Gene and the Risk of Late Toxicity After Radiotherapy in Prostate Cancer Patients	283
	<i>E.M. Thurner, S. Krenn-Pilko, W. Renner, A. Gerger, K.S. Kapp, U. Langsenlehner, T. Langsenlehner</i>	
034	Differential Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors	284
	<i>Y. Pommier, S.H. Huang, B.B. Das, A. Renaud, Y. Zhang, S.H. Takeda, J.H. Doroshow</i>	
035	The “Dbait”: a New Class of DNA Repair Inhibitors That Sensitize Tumors to Treatment	285
	<i>M. Dutreix, A. Croset, M. Quanz, J.S. Sun</i>	

- 036 MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor, Induces Differentiation in Acute Myelogenous Leukemia Cell Lines 286  
*M.P. Thomas, M.A. Milhollen, U. Naryanan, A. McDonald, M. Fleming, B. Amidon, M. Manfredi, P.G. Smith, A.J. Berger*
- 037 The “Dbait”: a New Class of DNA Repair Inhibitors, From Concept to the 1st-in-human Trial in Melanoma-in-transit 287  
*J.S. Sun, F. Devun, J. Biau, M. Dutreix, Group of Investigators*
- 038 Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer 288  
*S. Postel-Vinay, I. Bajrami, L. Friboulet, I. Jaco, Y. Fontebasso, K.A. Olaussen, J.C. Soria, F. André, C.J. Lord, A. Ashworth*
- 039 Assessment of a DNA-PK Inhibitor as a Chemo-potentiating Agent in Osteosarcoma 289  
*E. O'Reilly, B. Vormoor, S. Kyle, H. Newell*

### Heat Shock Proteins

- Poster board Abstract number
- 040 TAS-116, a Novel, Orally Bioavailable Highly Potent HSP90a/β Selective Inhibitor Demonstrates Favorable Tissue Distribution Properties Which Lead to Minimized Ocular Toxicity 290  
*Y. Kodama, H. Hitotsumachi, Y. Shibata, T. Suzuki, M. Sakuragi, M. Kitade, F. Morita, K. Yonekura, S. Ohkubo, T. Utsugi*
- 041 TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile 291  
*S. Ohkubo, H. Muraoka, A. Hashimoto, S. Ito, K. Ito, Y. Shibata, A. Kanoh, M. Kitade, K. Yonekura, T. Utsugi*
- 042 Evolution of Highly Selective HSP90a/β Inhibitors with Unique Binding Mode 292  
*C. Yoshimura, M. Kitade, H. Oshiumi, T. Uno, K. Chong-Takata, Y. Kawai, S. Yamashita, T. Mizutani, S. Ohkubo, T. Utsugi*
- 043 Activity of the HSP90 Inhibitor, AT13387, in ALK-driven Tumor Models 293  
*N. Wallis, T. Smyth, J. Munck, A. Rodriguez-Lopez, V. Lock, R. McMenamin, N. Thompson, J. Lyons*
- 044 Heat Shock Protein-90 (Hsp-90) Inhibitor, 17-AAG Blocks Transforming Growth Factor (TGF)-β1 Induced Epithelial-mesenchymal Transition (EMT) in A549 Cells 294  
*Y.S. Kim, J.O. Hong, H.L. Jang, J. Lee, S.H. Park, Y.S. Park, H.Y. Lim, W.K. Kang, J.O. Park*
- 045 Proteomic and Circulating Free DNA Analysis Outcome Predictors in the GALAXY Trial™ (NCT01348126): a Randomized Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIB/IV NSCLC 295  
*D.F. Fennell, E.F. Petricoin, J. Shaw, I. El-Hariry, V. Vukovic, F. Teofilovici, V. Reichert, R. Rosell*

### Hormonal Agents

- Poster board Abstract number
- 046 Relevance of CYP17A1 Blockade in Clones of Castration-resistant Prostate Cancer 296  
*J. Kumagai, S. Erkens-Schulze, N.F.J. Dits, R. de Wit, W.M. van Weerden*
- 047 Effectiveness of Acute Cycling of Supraphysiologic Testosterone Given Together with Etoposide in Men with Castration Resistant Prostate Cancer 297  
*S. Denmeade, H. Wang, A. Spitz, A. Pacheco, J.T. Isaacs, M.A. Carducci, E.S. Antonarakis*
- 048 Effect of Investigational Agent Orteronel (TAK-700) On Estrogen- and Corticoid-synthesis Pathways in Hypophysectomized Female Rats and On Serum Estradiol in Female Cynomolgus Monkeys 298  
*M. Yamaoka, T. Hara, T. Kaku, T. Hitaka, A. Tasaka, M. Kusaka*

### Met, Ret and Notch

- Poster board Abstract number
- 049 Development of Novel Combination Therapy with Dalotuzumab and GSI for the Treatment of Cetuximab Refractory Colorectal Cancer 299  
*G. Naumov, S. Howard, A. Seeley, C. Ware, J. Reilly, J. Cheng, S. Sathyanarayanan*
- 050 LY2801653: an Orally Bioavailable Small Molecule Kinase Inhibitor of MET with Inhibitory Activity Against the Oncoproteins ROS1 and MKNK1/2 300  
*M.N. Thobe, B.W. Konicek, V.L. Peek, J.A. Roseberry Baker, S.L. Um, J.R. Graff, R.A. Walgren, H. Pei, T.P. Burkholder, S.B. Yan*

051	Antitumor Activity of Ficlatazumab in Combination with Tivozanib On Primary Human Renal Cell Carcinoma Xenografts <i>K. Meetze, K. Connolly, B. Feng, W. Rideout, J. Gyuris, M. Han</i>	301
052	Antitumor Activity of Ficlatazumab in Combination with Cetuximab On Squamous Cell Carcinomas of the Head and Neck <i>K. Meetze, K. Connolly, K. Clark, J. Gyuris, M. Han</i>	302
053	Combination Effect of Tivantinib with Erlotinib On Cell Proliferation, C-Met Signals and Apoptosis in a Human Non-small Cell Lung Cancer Cell Line <i>F. Koizumi, K. Ishii, S. Soga, S. Akinaga, H. Ishida, T. Takahashi</i>	303
054	Notch in Breast Cancer: Preclinical and Clinical Studies <i>P.M. McGowan, E.W. McDermott, J. Crown, N. O'Donovan, M.J. Duffy</i>	304
055	Notch 4: a Paradoxical Role in Breast Cancer Progression? <i>P.M. McGowan, J. Sigmans, S.F. Madden, E.W. McDermott, J. Crown, M.J. Duffy</i>	305
056	Excessive MET Signaling Causes Acquired Resistance to and Addiction to MET Inhibitors in MKN45 Gastric Cancer Cell Line <i>Y. Funakoshi, T. Mukohara, H. Tomioka, R.C. Ekyalongo, Y. Kataoka, Y. Inui, Y. Kawamori, N. Kiyota, Y. Fujiwara, H. Minami</i>	306
057	Anti-tumor Activities of Lenvatinib Against RET Gene Fusion Driven Tumor Models <i>K. Okamoto, K. Kodama, K. Takase, K. Nakamoto, H. Coffey, A. Selvaraj, P.G. Smith, M. Iwata, A. Tsuruoka</i>	307
058	HGF/VEGF Dual Signaling Regulates Bone Metastatic Prostate Cancer Proliferation and Osteoclast Differentiation <i>H. Fujita, C. Matsumoto, K. Yonekura, S. Yokoyama, K. Watanabe, M. Hirata, C. Miyaura, T. Utsugi, M. Inada</i>	308
059	Characterization of a Novel, Highly Potent and Selective RET Inhibitor with Antitumor Efficacy in RET Dependent Models <i>E. Ardini, N. Amboldi, N. Avanzi, P. Banfi, C. Cristiani, D. Donati, A. Galvani, A. Isacchi, E. Pesenti, M. Menichincheri</i>	309
060	Comparative Study of Nanog, Oct3/4 and Sox2 Gene Expression Following C-Met Gene Knockdown in Colon Cancer Stem Cells <i>M. Chatziioannou, P. Apostolou, M. Toloudi, E. Ioannou, R. Hammon, U. Jacob, A. Kopic, N. Hembry, D. Komiotis, I. Pappasotiriou</i>	310
061	Vandetanib Can Overcome the Acquired Resistance to Gefitinib Due to RET Overexpression in Lung Cancer <i>M. Sunohara, M. Kawakami, K. Watanabe, S. Morita, H. Kage, Y. Amano, M. Fukayama, T. Nagase, N. Ohishi, D. Takai</i>	311
062	A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study <i>M. Fournel, J. Wang, N. Beaulieu, C. Bonfils, H. Hurwitz, G. Shapiro, C.K. Kollmannsberger, M. Juretic, J.M. Besterman, C.R. Maroun</i>	312
063	A Pooled Analysis to Evaluate the Incidence of Proteinuria, Hypoalbuminemia, and Edema Secondary to MET and VEGFR Inhibition <i>P. Bradbury, E. Eisenhauer, D. Rayson, S. Lupichuk, S. Chia, N. Leighl, C. Ho, L. Seymour</i>	313
064	Biomarker Analysis in the First-in-human OMP-59R5 (anti-Notch2/3) Phase I Study Demonstrates Pharmacodynamic (PD) Modulation of the Notch Pathway in Patients with Advanced Solid Tumors <i>A. Tolcher, A.M. Kapoun, M. Wang, C. Zhang, A. Patnaik, K. Papadopoulos, R. Chugh, V. Thorpe, J. Dupont, D.C. Smith</i>	314

### Monoclonal Antibodies and Targeted Toxins/Nuclides

Poster board

Abstract number

065	ImmunoPET and Biodistribution with Human Epidermal Growth Factor Receptor 3 Targeting Radiolabeled Antibody 89Zr-GE-huMAb-HER3 <i>A.G.T. Terwisscha van Scheltinga, M.N. Lub-de Hooge, K. Abiraj, C.P. Schröder, L. Pot, B. Bossenmaier, M. Pickl, T. Friess, J.G.W. Kosterink, E.G.E. de Vries</i>	315
-----	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

- 066 MM-141, a Novel Bispecific Antibody Co-targeting IGF-1R and ErbB3, Inhibits PI3K/Akt/mTOR Pro-survival Signaling in Preclinical Cancer Models 316  
*J. Baum, B. Johnson, S. Adams, J. Tang, S. Iadevaia, B. Schoeberl, U. Nielsen, J. Fitzgerald, A. Lugovskoy*
- 067 Schedule Dependent Tumor Cell Response to Radiation When Combined with Anti-IGF1R and Anti-EGFR Antibodies 317  
*U. Raju, D. Molkenhine, D. Valdecanas, K.K. Ang*
- 068 Effects of Radiologic Tumor Response of Anti-Glypican-3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular Carcinoma 318  
*G.K. Abou-Alfa, B. Zhao, J.F. Chou, J. Ma, M. Capanu, M. Koga, R. Lee, T. Othomo, J. Germino, L. Schwartz*
- 069 Anti-PSMA X Anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-resistant Prostate Cancer Models 319  
*T. Sewell, G. Hernandez-Hoyos, R.A. Chenault, J. Wiens, J. Kumer, S. Natarajan, C.J. McMahan, P.A. Algate, J.W. Blankenship*
- 070 Comparative Pharmacokinetics of Trastuzumab-US and Trastuzumab-EU and the Potential Biosimilar Trastuzumab-Pfizer in Male CD-1 Mice 320  
*A.M. Ryan, S. Hurst, J.M. McNally, L.G. Lorello, G.L. Finch, M.W. Leach, S.A. Ploch, J.A. Fohey, T.A. Smolarek*
- 071 Analysis of Combinatorial Effect of Multikinase Inhibitor (Sorafenib, Sunitinib) or Cetuximab with MEK or mTOR Inhibitors in Human Head and Neck Cancer Cells 321  
*H. Byeon, Y. Koh, W. Kim, J. Kim, H. Hong, Y. Yang, H. Na, E. Choi*
- 072 Efficacy of Amanitin Conjugated Chimeric Anti-EpCAM Monoclonal Antibody in Experimental Carcinomas 322  
*A.V. Salnikow, G. Moldenhauer, S. Lüttgau, I. Herr, J. Anderl, H. Faulstich*
- 073 A Pilot Study of the Safety, Efficacy and Effects On Functional Imaging of the Combination of CG250 and Sunitinib in Patients (pts) with Advanced Renal Cell Carcinoma (RCC) 323  
*M. Ciprotti, I.D. Davis, D.W. Pook, F.T. Lee, S.T. Lee, G.J. O'Keefe, H. Tochon-Danguy, F.E. Smyth, W. Hopkins, A.M. Scott*
- 074 Monoclonal Antibodies Against Novel Tumor Markers for Diagnostic Prognostic and Predictive Applications 324  
*R. Grifantini, P. Pileri, M. Parri, A. Grandi, S. Campagnoli, E. De Camilli, G. Viale, S. Eppenberger, V. Terracciano, G. Grandi*
- 075 MM-121 (SAR256212), an Anti-ErbB3 Monoclonal Antibody, Shows Synergistic Tumor Growth Inhibition in Combination with a Pan-PI3K Inhibitor or a Microtubule Inhibitor Through ErbB3 Expression Modulation 325  
*C. Henry, C. Geslin, A.M. Blanchet, C. Nicolazzi, G. Garcia, L. Vincent, V. Blanc, I. Tabah-Fisch, M. Chiron*
- 076 Acute Myeloid Leukemia (AML) Cell Lines Are Sensitive to the Anthrax Lethal Toxin (LeTx)-Mediated Inhibition of the MAPK Pathway 326  
*R. Abi-Habib, E. Kassab, M. Darwish, Z. Timsah, S. Liu, S. Leppla, A. Frankel*
- 077 Phase II Study of Cetuximab and Lenalidomide in Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck 327  
*R. Taylor, S. Wong, A. Chan, L. Silipino, V. Villaflor, E. Vokes, J. de Souza, T. Seiwert, E. Cohen*
- 078 <sup>124</sup>I GC33 Positron Emission Tomography (PET), Imaging Biomarker of Glypican-3 in Hepatocellular Carcinoma 328  
*G.K. Abou-Alfa, J.A. O'Donoghue, B. Gansukh, J. Ma, S. Ruan, M. Koga, R. Lee, N. Ohishi, T. Othomo, J.A. Carrasquillo*
- 079 The Investigational Drug MLN0264 First-in-human, First in Class ADC Targeting GCC: Phase I Dose-escalation Study and Supportive Scientific Rationale 329  
*P. Veiby, J. Zhang, J. Yang, A. McDonald, A. Fasanmade, T. Wyant, K. Almhanna, T. Kalebic*
- 080 Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a LHRH Receptor Targeting Peptide Interfere with Cell Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth in a LHRH Receptor Positive Ovarian Cancer Xenograft Model 330  
*B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R. Jansen, R. Mueller, E. Guenther, M. Gerlach, M. Teifel*



- 081 MEDI3379, an Antibody Against HER3, is Active in Heregulin or HER2-driven Human Tumor Models 331  
*P. Steiner, K. Kinneer, K. Schifferli, R. Rothstein, R. Carrasco, R. Tammali, R. Hollingsworth, D. Tice, Z. Xiao*
- 082 The Anti-tyrosinase Monoclonal Antibody is Effective in Treating Mice Bearing Syngenic Melanoma 332  
*N. Jaanson, K. Gildemann, M. Ustav*

### mTOR

- | Poster board                                                                                                                                                                                                                                                                                                                                                    | Abstract number |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 083 Preclinical Testing of Everolimus in Combination with Standard Endocrine Treatments in Hormone-resistant Patient-derived Luminal Breast Cancer Xenografts<br><i>E. Marangoni, T. Bagarre, F. Assayag, S. Chateau-Joubert, J.J. Fontaine, K. Slimane, I. Bièche, D. Decaudin, A. Vincent-Salomon, P. Cottu</i>                                               | 333             |
| 084 Gene Expression Analysis of Human Sarcoma Tissues to Explore Clinical Outcomes of mTOR Inhibition with Ridaforolimus: Correlative Science From the Phase III SUCCEED Trial Testing Maintenance Therapy for Metastatic Disease<br><i>T. Zhang, S. Ebbinghaus, A. Loboda, M. Nebozhyn, J. Lunceford, B. Haines, V. Rivera, C. Sant, G. Demetri, J.Y. Blay</i> | 334             |
| 085 mTOR Inhibitor CC-223 Acts in Synergy with Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Non-Small Cell Lung Cancer Cell Lines<br><i>S. Ekman, M.W. Wynes, D. Chan, K. Hege, S. Xu, F.R. Hirsch</i>                                                                                                    | 335             |
| 086 Antitumor Activity of mTOR Kinase Inhibitor CC-223 in a Mouse Model of Glioblastoma<br><i>R.K. Narla, S. Peng, J. Katz, J. Apuy, M. Moghaddam, K. Fultz, S. Sankar, D. Mortensen, H.K. Raymon</i>                                                                                                                                                           | 336             |
| 087 The Discovery and Preclinical Characterization of CC-223, a Novel mTOR Kinase Inhibitor Under Clinical Investigation<br><i>D.S. Mortensen, K.E. Fultz, M. Hickman, G. Khambatta, W. Xu, S.M. Perrin-Ninkovic, J. Zhao, R.K. Narla, H. Raymon, S. Sankar</i>                                                                                                 | 337             |
| 088 CC-223, a Selective mTOR Kinase Inhibitor, Potently Inhibits Proliferation of a Large Panel of Cancer Cell Lines in Vitro<br><i>S. Xu, T. Tran, T. Tsuji, L. Sapinoso, K.E. Fultz, W. Xu, S. Sankar, A. Lopez-Girona, P. Worland, D.S. Mortensen</i>                                                                                                        | 338             |
| 089 Activities of Rapalog mTOR Inhibitors Everolimus and Temsirolimus in Patient-derived Tumors Engrafted in Nude Mice: Association with Molecular Determinants<br><i>V. Vuaroqueaux, A. Maier, A.L. Peille, R. Krumbach, J. Viraya, F. Foucault, T. Giesemann, T. Metz, T. Metcalfe, H.H. Fiebig</i>                                                           | 339             |
| 090 The Development of New Metformin-Derivative to Target Breast Cancer Stem Cells<br><i>K. Lee, W. Han, D. Noh</i>                                                                                                                                                                                                                                             | 340             |

### Paediatric-Early Drug Development

- | Poster board                                                                                                                                                                                                               | Abstract number |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| 091 Cytotoxic Screen Unveils a Novel Inhibitor of Low Grade Pediatric Astrocytomas Belonging to a Family of Steroid Inhibitor Compounds<br><i>D. Poirier, N. Ajeawung, R. Maltais, D. Kamnasaran</i>                       | 341             |
| 092 Dipotassium Bisperoxo Oxovanadate V Inhibits the Growth of Pediatric Low Grade Astrocytomas<br><i>R. Faure, N. Ajeawung, D. Kamnasaran</i>                                                                             | 342             |
| 093 Brominated Noscapiine Inhibits the Growth of Pediatric Low Grade Astrocytomas<br><i>N. Ajeawung, H. Joshi, D. Kamnasaran</i>                                                                                           | 343             |
| 094 A Phase I Study of Histone Deacetylase Inhibitor, SB939, in Pediatric Patients with Refractory Solid Tumors<br><i>A.P. Zorzi, M. Bernstein, Y. Samson, D.A. Wall, S. Desai, N. Wainman, E. Eisenhauer, S. Baruchel</i> | 344             |
| 095 Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin<br><i>M. Smith, M. Kang, R. Lock, H. Carol, R. Gorlick, A. Kolb, J. Maris, S. Keir, R. Kurmasheva, P. Houghton</i>                         | 345             |

- 096 First in Pediatrics Phase I Study of Crenolanib Besylate (CP-868,596-26) Administered During and After Radiation Therapy (RT) in Newly-diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Recurrent High Grade Glioma, Including DIPG (HGG) 346  
*C. Wetmore, A. Broniscer, K.D. Wright, A. Pai-Panandiker, Z. Patay, A. Onar-Thomas, A. Ramachandran, A. Gajjar, D.C. Turner, C.S. Stewart*
- 097 Efficacy of Dasatinib in Targeting Diffuse Intrinsic Pontine Glioma (DIPG) Specific Pathway Activation in Vitro 347  
*N. Truffaux, S. Puget, G. Vassal, B. Geoerger, J. Grill*

**PARP**

- Poster board Abstract number
- 098 Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures) 348  
*M.J. Patterson, J. Murray, N.J. Curtin*
- 099 Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699) 349  
*B. Vormoor, S. Wilkinson, F. Harvey, R. Plummer, N. Curtin*
- 100 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas 350  
*Y. Pignochino, F. Capozzi, C. Dell'Aglio, M. Basiricò, L. D'ambrosio, D. Galizia, E. Palesandro, M.S. Benassi, M. Aglietta, G. Grignani*
- 101 Temozolomide-sensitizing Effects of ABT-888 Are Limited to Inherently TMZ-sensitive MGMT Hypermethylated GBM Xenografts 351  
*J.N. Sarkaria, S.K. Gupta, B.L. Carlson, A.C. Mladek, L. Cen, M.A. Schroeder*
- 102 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients 352  
*S.K. Sandhu, G. Wilding, W.R. Schelman, A. Omlin, N. Kreischer, C. Carpenter, R. Iannone, S. Kaye, J.S. de-Bono, R.M. Wenham*

**PI3 Kinase**

- Poster board Abstract number
- 103 High Nuclear Expression of GSK-3 Beta and Low Membrane Expression of Beta-catenin Are Markers of Poor Prognosis in Colon Cancer 353  
*T. Salim, J. Sand-Dejmek, A. Sjölander*
- 104 Exploration of the Role of Ras-PI3K Interaction in Lung Tumor Maintenance 354  
*C. Sheridan, E. Castellano, M. Murillo, J. Downward*
- 105 A Novel Highly Potent AKT Inhibitor TAS-117 Demonstrated Synergistic Antitumor Activity in Combination with Paclitaxel Through Enhancement of Apoptosis Induction 355  
*K. Ichikawa, T. Abe, H. Fukushima, R. Fujita, M. Okada, K. Yonekura, T. Shimomura, T. Utsugi*
- 106 Characterization of TAS-117, a Novel, Highly Potent and Selective Inhibitor of AKT 356  
*T. Abe, K. Ichikawa, R. Fujita, M. Okada, K. Tanaka, N. Fujino, M. Ohkubo, K. Yonekura, T. Shimomura, T. Utsugi*
- 107 ZSTK474, a Specific PI3K Inhibitor, Induces Mesenchymal to Epithelial Transition in Vivo 357  
*M. Okamura, S. Dan, H. Yoshimi, T. Yamori*
- 108 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer 358  
*C. Britten, Z. Wainberg, J. Tabernero, M. Alsina Maqueda, S. Leong, C. Sessa, R. Millham, J. Gallo, L. Siu, I. Brana*
- 109 Tumor Pharmacodynamic Assessments by Reverse Phase Protein Array Reveal Broad Pathway Inhibition in Patients Treated with an AKT Kinase Inhibitor 359  
*Y. Yan, V. Serra, L. Prudkin, M. Scaltriti, S. Murli, M.R. Lackner, A. Cervantes, J. Tabernero, P. Patel, J. Baselga*
- 110 Efficacy of a Brain-penetrant PI3K/mTOR Inhibitor in Orthotopic Models of Glioblastoma 360  
*L. Salphati, T.P. Heffron, B. Aliche, K. Barck, R.A. Carano, S. Kharbanda, L.B. Lee, M. Nishimura, A.G. Olivero, H.S. Phillips*

111	Anti-tumor Efficacy Profile of a Novel Dual PI3K/mTOR Inhibitor, DS-7423 <i>Y. Hirota, K. Sato, Y. Hama, Y. Nagashima, R. Watanabe, N. Suzuki, M. Sugimura, Y. Shiose</i>	361
112	Anti-tumor Efficacy of DS-7423, a Novel PI3K/mTOR Dual Inhibitor, in Ovarian Clear Cell Adenocarcinoma <i>T. Kashiyama, K. Oda, Y. Ikeda, Y. Shiose, Y. Hirota, A. Miyasaka, O. Wada-Hiraike, K. Kawana, T. Yano, S. Kozuma</i>	362
113	A Dual PI3K/mTOR Inhibitor DS-7423 is Effective in in Vitro and in Vivo Models of Glioblastoma Cell Lines and Glioma Stem Cells <i>D. Koul, S. Wang, J. Fu, J. Yao, W.K. Yung</i>	363
114	Prognostic Value of PI3KCA Mutations in 228 Consecutive Triple Negative Breast Cancers <i>P.J. Lamy, C. Mollevi-Bascoul, A.C. Laberenne, F. Bibeau, R. Senal, G. Romieu, W. Jacot</i>	364
115	A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors <i>M. Lolkema, S. Leong, E. Voest, E. Freas, G. Shankar, R.K. Brachmann, R.A. Moss, M.N. Stein, M. Mergui-Roelvink, J.H.M. Schellens</i>	365
116	Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors <i>J. Rodon Ahnert, H.A. Burris, J.H.M. Schellens, M. Schuler, O. Goodman, C. Britten, D. Richards, D. Demanse, A. Silva, J. Baselga</i>	366
117	BAY80-6946 is a Potent and Selective PI3K Inhibitor That Induces Apoptosis in Breast Cancers by Blocking AKT and Non-AKT PI3K Effector Pathways <i>M. Will, W. Toy, P. Payal, V. Rodrik-Outmezguine, C. Schneider, J. Paul, N. Liu, N. Rosen, S. Chandarlapaty</i>	367
118	GDC-0068, a Novel and Selective Akt Inhibitor Demonstrates Improvement in Anti-tumor Activity When Combined with Androgen Receptor Pathway Antagonists, MDV3100 and Abiraterone, in Prostate Cancer Models <i>M.A. Nannini, A. Arrazate, J. Bower, L.B. Lee, J. Lin, B.B. Lee, R. Kassees, K. Lin, D. Sampath</i>	368
119	Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib <i>M. Serova, A. Raballand, C. Dos Santos, E. Riveiro, E. Raymond, S. Faivre, A. de Gramont</i>	369
120	Identification of IGF1R as a Predictive Biomarker for Intrinsic Resistance to PI3K Inhibitors and a Therapeutic Target for Improving the Drug Efficacy <i>S. Dan, S. Isoyama, Y. Nishimura, G. Kajiwara, N. Nakamura, T. Yamori</i>	370

### Signal Transduction Modulators

	Poster board	Abstract number
121	Impact of Targeted Therapy with Lapatinib in Metastatic Breast Carcinoma <i>M. Behera, P.K. Julka, G.K. Rath</i>	371
122	Preclinical Characterization of RG7256, a Potent and Selective BRAF Inhibitor with Differentiation From Vemurafenib <i>F. Su, L. Xu, B. Higgings, H. Yang, K. Packman, H. Hilton, K. Schostack, G. Bollag, J. Tsai, G. Habets</i>	372
123	A Quantitative Proteomic Analysis Identifies Neddylated Proteins Regulated by the Investigational NEDD8-activating Enzyme Inhibitor MLN4924 <i>X. Liu, J. Blank, H. Liao, E. Lightcap</i>	373
124	CPAP is a Novel Transcriptional Co-activator of NF-kB <i>L. Hung, S. Yang, K. Chang, C. Yen, Y. Lin, P. Chang-Liao, J. Tsou, W. Hung, T. Tang, Y. Liu</i>	374
125	Dual PI3K/mTOR and HER2 Blockade Results in Antitumor Efficacy in Preclinical Models of HER2+ Breast Cancer Resistant to Trastuzumab Therapy <i>P. De, Y. Sun, N. Dey, B. Leyland-Jones</i>	375
126	Wnt-beta-catenin Pathway Controls Metastasis-associated Phenotypes of Tumor Cells in the Triple Negative Subset of Breast Cancer: a Proof of Concept Study <i>N. Dey, W. Hui, P. De, B. Leyland-Jones</i>	376
127	Selective Inhibition of AKT Protein Isoforms Augments Gefitinib Response in EGFR Mutated NSCLC Cells <i>S.M. Bokobza, A.M. Devery, A.M. Weber, Y. Jiang, A.J. Ryan</i>	377

- 128 Differential Targeting of KRAS and BRAF Mutant Tumors Using MEK Inhibitors with Distinct Mechanisms of Action 378  
*G. Hatzivassiliou, J. Haling, H. Chen, K. Song, A. Peck, K. Hoeflich, L. Friedman, S. Malek, M. Belvin*
- 129 The Anti-tumor Agent, Dp44mT, Differentially Targets the AKT, TGF-beta and ERK Pathways Via the Metastasis Suppressor NDRG1 in Normal Prostate Epithelial Cells and Prostate Cancer Cells 379  
*G.Y.L. Lui, K.M. Dixon, Z. Kovacevic, M. Yao, Z. Chen, Q. Dong, S.J. Assinder, D.R. Richardson*
- 130 Identification & Biological Characterization of a Highly Potent, Irreversible Inhibitor of FGFR, TAS-2985 380  
*H. Sootome, H. Fujita, H. Ochiwa, K. Ito, T. Sagara, M. Chiba, H. Hirai, Y. Iwasawa, T. Utsugi*
- 131 Investigation of RasGRP3 Expression and Function in Human Breast Cancers and Breast-derived Ductal Adenocarcinoma Cell Lines 381  
*Z. Nagy, E. Orosz, I. Kovács, M. Török, T. Biró, P.M. Blumberg, G. Czifra*
- 132 Preclinical Pharmacokinetics of GE-huMab-HER3, a Novel Humanized, Glycoengineered Anti-HER3 Antibody Using PHER3/HER3 Ratio as Pharmacodynamics (PD) Marker 382  
*G. Meneses-Lorente, I. Kolm, M. Thomas, T. Friess, S. Bader, C. Meille, B. Bossenmaier*
- 133 Significant in Vivo Antitumor Activity by a Highly Potent, Irreversible FGFR Inhibitor, TAS-2985 383  
*Y. Nakatsuru, H. Fujita, H. Sootome, H. Ochiwa, K. Ito, Y. Shibata, M. Mitsuya, H. Kazuno, H. Hirai, T. Utsugi*
- 134 Synergistically Reduced Malignancy of Human Breast Cancer Cells Due to Co-Silencing of HER2 and PTK6 384  
*N. Ludyga, N. Anastasov, M. Rosemann, I. Höfig, J. Seiler, H. Braselmann, K. Mengele, M. Schmitt, H. Höfler, M. Aubele*
- 135 Dovitinib, a Multitargeted Kinase Inhibitor, Actively Inhibits Human Gastric Cancer Cells Via On-target Effects, and Acts Synergistically with 5-fluorouracil Via Off-target Effects with Down-regulation of Thymidylate Synthase 385  
*K.H. Yeh, C.H. Gao, A.L. Cheng*
- 136 Evaluation of Crenolanib (CP-868,596) for the Treatment of FLT3-ITD-positive AML 386  
*E.I. Zimmerman, S. Hu, S. Orwick, J. Berk, L. Li, C. Drenberg, M. Roberts, A. Ramachandran, C.F. Stewart, S.D. Baker*
- 137 The Focal Adhesion Kinase Inhibitor GSK2256098: a Potent and Selective Inhibitor for the Treatment of Cancer 387  
*K.R. Auger, K.N. Smitheman, S. Korenchuk, C. McHugh, R. Kruger, G.S. Van Aller, A. Smallwood, R.R. Gontarek, T. Faitg, N. Johnson*
- 138 Preclinical Characterization of RP7047, a Novel and Selective Inhibitor of Pyrimidine Synthesis for the Treatment of Acute Lymphoblastic Leukemia 388  
*S. Viswanadha, R. Prasanna, G.S. Merikapudi, S. Veeraraghavan, S. Vakkalanka*
- 139 Contribution of OATP1B-type Carriers to the Hepatic Elimination of Sorafenib 389  
*J.L. Roberts, E.I. Zimmerman, S. Hu, L. Li, A.A. Gibson, A. Sparreboom, S.D. Baker*
- 140 Methylnaltrexone Inhibits Opioid- and Growth Factor-Induced Human Lung Cancer Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) 390  
*P.A. Singleton, F.E. Lennon, T. Mirzapioazova, B. Mambetsariev, V. Poroyko, R. Salgia, J. Moss*
- 141 Assessment of the Combination of PF-04691502 (PI3K/mTORi) and PD-0325901 (MEKi) Against Colorectal Cell Lines and Patient-derived Xenograft Models 391  
*T.P. Newton, T.M. Pitts, R.M. Addison, S.M. Bagby, K.L. McPhillips, H.L. Selby, S.G. Eckhardt, S. Leong*
- 142 Genome-wide shRNA Library Screen Identifies CASPASE 8 as a Gene Sensitizing Ovarian Cancer Cells to IKK $\beta$  Inhibition 392  
*L. Hernandez, H. Kohlhammer, L. Staudt, C.M. Annunziata*
- 143 TAK-733, an Investigational Novel MEK Inhibitor, Suppresses Colorectal Cancer (CRC) Tumor Growth in Biomarker Positive Patient-derived Human Tumor Explants 393  
*C.H. Lieu, J.L. Tentler, A.C. Tan, T.M. Pitts, A. Spreafico, H.M. Selby, K.L. McPhillips, S.M. Bagby, S.G. Eckhardt*
- 144 MicroRNA-99a, a Tumor Suppressor in Oral Squamous Cell Carcinoma Regulates Insulin-like Growth Factors I Receptor in a Double-negative Feedback Loop 394  
*Y.C. Yen, S.G. Shiah, H.C. Chu, J.R. Hsiao, J.Y. Chang, C.T. Liao, A.J. Cheng, Y.C. Lu, Y.W. Chen*

- 145 Discovery of CPL-407-22 – Novel, Potent and Highly Selective JAK2 Kinase Inhibitor 395  
*K. Dzwonek, M. Mroczkiewicz, F. Stefaniak, P. Gunerka, D. Zdzalik, B. Dymek, P. Grygielewicz, M. Lamparska-Przybysz, M. Wieczorek*
- 146 A Phase I, Dose-finding Study of BI 853520, a Potent and Selective Inhibitor of Protein Tyrosine Kinase 2 in Patients with Advanced or Metastatic Solid Tumors 396  
*M. de Jonge, S. Sahebjam, R.H. Mathijssen, A. Razak, D. van der Biessen, L.C. Pronk, D. Schnell, L.L. Siu*
- 147 Epidermal Growth Factor Receptor (EGFR) Expression Levels Predict Cetuximab Activity in Non-small-cell Lung Cancer (NSCLC) 397  
*C. Stroh, E. Staub, M. Friese-Hamim, S. Störkel, C. Amendt*
- 148 Benchmarking the Allosteric MEK Inhibitors UO126, AZD6244, AS703026, and GSK1120212 Shows Differences in Potency to Inhibit ERK Phosphorylation, Proliferation, and Invasion in Pancreatic Cancer Models 398  
*C. Neuzillet, M. Serova, A. Raballand, L. Astorgues-Xerri, M.E. Riveiro, A. de Gramont, P. Ruzzniewski, P. Hammel, S. Faivre, E. Raymond*
- 149 Pharmacokinetics and Pharmacodynamics of TAK-733, an Investigational, Oral MEK Inhibitor, in Patients with Advanced Nonhematologic Malignancies 399  
*X. Zhou, S. Faucette, S. Kaun, E. Gangolli, V. Bozon, K. Venkatakrishnan*
- 150 FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in Vivo 400  
*Q. Xu, V.N. Kolev, C.M. Vidal, I.M. Shapiro, J.E. Ring, M.V. Padval, M. Keegan, J.A. Pachter*
- 151 Impact of Saridegib (IPI-926) On Smoothed Ciliary Localization and Hedgehog Pathway Activity 401  
*M. Peluso, K. Faia, V. Campbell, J. DiNitto, J. Harari, J. Proctor, M. Pink, K. McGovern, J. Kutok, M. Read*
- 152 Dual Inhibition of the MEK and the PI3K-Akt-mTOR Pathways Using GSK1120212 (or UO126) and Everolimus Overcomes Resistance to MEK Inhibitors Used as Single Agents in Pancreatic Cancer Cells 402  
*C. Neuzillet, M. Serova, A. Raballand, L. Astorgues-Xerri, M.E. Riveiro, A. de Gramont, P. Ruzzniewski, P. Hammel, S. Faivre, E. Raymond*
- 153 AZD1480 is a Potent Inhibitor of ROS1 and Induces Regression in ROS1 Fusion Containing Cancer Models 403  
*L. Drew, M. Shen, T. Patterson, T. Cheung, M. Hattersley, E. Hennessy, N. Guan, C. Denz, M. Scarpitti, P. McCoon*
- 154 LY2228820 Dimesylate, a P38 MAPK Inhibitor, Demonstrates Anti-Neoplastic Activity in Mouse Models of Human Ovarian Cancer 404  
*S. Pratt, R. Gilmour, N. Brooks, E. Chan, L. Stancato*
- 155 The Pan-PI3K/mTORKinase Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells in Breast Cancer Models 405  
*J.A. Pachter, V.N. Kolev, A.A. Neill, Q.G. Wright, M.V. Padval, Q. Xu*
- 156 PHT-782 an Inhibitor of the KRAS Signaling Nanocluster Protein CNKSR1 Blocks Oncogenic KRAS Signaling 406  
*N. Ihle, M.F. Abdelmelek, S. Zhang, M. Indarte, D.L. Kirkpatrick, G. Powis*
- 157 A Broad Tumor Cell Line Panel Screen of Ponatinib, a Pan-BCR-ABL and Multitargeted Kinase Inhibitor 407  
*J. Gozgit, T. Chen, A. Schrock, T. Clackson, V.M. Rivera*
- 158 Development of Assays for Discovery of Cell-active Tankyrase Inhibitors 408  
*V. Chell, T. Brooks, J. Wayne, J.D. Moore, H. Brazier, T. Shaw, L. Baker, A. Massey, C. Graham, A.T. Macias*
- 159 Optimizing the Therapeutic Potential of PD-L1 Blockade as a Single Agent and Through Combination Therapy 409  
*B. Irving, H. Maecker, Y. Yang, M. Moskalenko, J. Cheung, D. Chen*
- 160 Circumventing Paradoxical Drug-induced Activation of the MAPK Pathway with Next Generation B-RAF V600E Inhibitors 410  
*J.M. Vernier, D. Matthews, P. Pearson, S. Hershenson, J. Freddo, A.J. Giaccia, R. Tabibiazar, P.M. O'Connor*
- 161 The miR-106b-25 Cluster as a Potential Target for Six1-mediated Breast Cancer Metastasis, and a Molecular Marker of the TGF $\beta$  Paradox 411  
*A.L. Smith, R. Iwanaga, D.J. Drasin, D.S. Micalizzi, R.L. Vartuli, H.L. Ford*

- 162 Antitumor Activity of BM-1197, a Dual Inhibitor of Bcl-2 and Bcl-xL, in Small Cell Lung Cancer Tumors 412  
*L. Bai, J. Chen, D. McEachern, L. Liu, H. Zhou, A. Aguilar, C.Y. Yang, J.L. Meagher, J.A. Stuckey, S. Wang*
- 163 Targeting HdmX as a Therapeutic Approach for Cancer 413  
*D. Wald, M. Agarwal, A. Chakrabarti*
- 164 The Anti-tumor Activity of the ERBB3 Inhibitory Antibody AV-203 in Patient Derived Tumor Explant Models 414  
*K. Meetze, S. Tyler, K. Clark, E. Mazsa, A. Delpero, J. Gyuris, S. Vincent*
- 165 Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer 415  
*S. Mohd Nafi, A. Kong, M. Gijsen, G. Kramer-Marek, J. Capala*
- 166 XGFR\* is a Novel Tri-functional Anti-EGFR/IGF-1R Antibody Blocking Key Tumor Signaling Pathways and Activating Host Immune Functions for Targeted Treatment of Pancreatic Cancer 416  
*T. Friess, J.M. Schanzer, E. Ruge, N. Dimoudis, S. Hoves, C.H. Ooi, T. Otz, M. Bacac, M. Weisser, K. Wartha*
- 167 A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer 417  
*S. Chandarlapaty, V. Rodrik-Outmezguine, M. Maurizio Scaltriti, R. Sakr, M. Will, D. Giri, C. Hudis, J. Baselga, T. King, N. Rosen*
- 168 Inhibition of IGF1R with Ganitumab Switches Pancreatic Cancer Cells to Oxidative Metabolism 418  
*P.J. Beltran, E. Cajulis, Y.A. Chung, P. Mitchell, L.U. Ming, R.S. Finn, F.J. Calzone*

### **Tubulin-Interacting Agents**

#### Poster board

#### Abstract number

- 169 Reduced Affinity of Eribulin for  $\beta$ III-tubulin: a Role in Reduced Neuropathy? 419  
*M.A. Jordan, H.P. Miller, M. Lopus, A. Azarenko, L. Wilson*
- 170 Increased Clearance of Docetaxel in Androgen Deprived Prostate Cancer Patients 420  
*A.J.M. Nieuweboer, A.J. de Graan, M.J.A. de Jonge, P. de Bruijn, L.E. Friberg, L. van Doorn, E.A.C. Wiemer, R. de Wit, R.H. Mathijssen*
- 171 Dual Mechanism of Action of the Novel Microtubule-targeting Drug BAL27862 (active Moiety of the Prodrug BAL101553): Targeting Tumor and Vascular Cells 421  
*F. Bachmann, H. Lane*
- 172 Antitumor Activity of BAL27862 (active Moiety of the Prodrug BAL101553) is Associated with the Generation of Short Non-centrosomal Microtubules 422  
*A. Rovini, S. Honoré, N. McKay, F. Bachmann, H.A. Lane, D. Braguer*
- 173 EB1 Overexpression Promotes Glioblastoma Progression and Sensitizes to Microtubule-targeting Agents in Vitro and in Vivo 423  
*R. Berges, A.F. Blandin, A. Kruczynski, D. Braguer, S. Honore*
- 174 Taxane Efficacy is Positively Related to Intratumoral Concentrations in Patient-derived Prostate Cancer Xenografts 424  
*E.S. de Morrée, C.M. de Ridder, P. de Bruijn, H. Burger, E.A.C. Wiemer, R.H. Mathijssen, R. de Wit, W.M. van Weerden*
- 175 Structure Activity Relationship of a Novel Chemical Class of Microtubule-disrupting Agents 425  
*L. Desire, A.S. Casagrande, F. Bachelot, S. Coutadeur, F. Maurier-Mahe, B. Leblond, E. Beausoleil, T. Taverne, C. Chauvignac, M. Pando*

## Friday 9 November 2012

### Plenary Session 8

**Auditorium**  
Abstract number

11:00–12:45	<b>Drug Resistance in Targeted Agents</b> Chairs: R. Bernards (The Netherlands) and A. Letai (USA)	
11:00	Using Functional Genetics to Optimize the Treatment of Cancer <i>R. Bernards (The Netherlands)</i>	426
11:25	The mitochondrial basis of resistance to BCL-2 antagonists and conventional chemotherapy <i>A. Letai (USA)</i>	427
11:50	Resistance to Targeted Therapies in Lung Cancer <i>T. Bivona (USA)</i>	428
12:15	Reversing Resistance to Targeted Therapies in Breast Cancer <i>F. Andre (France)</i>	429

### Poster Sessions

#### Biomarkers

Poster board	Abstract number
001 Analysis of 2,700 Cancer Exomes to Identify Novel Cancer Drivers and Therapeutic Opportunities <i>S.A. Tomlins, P. Wyngaard, N. Khazanov, P. Williams, E. Bowden, S. Sadis, D.R. Rhodes</i>	430
002 A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles <i>A. Chakravarti, M. Wang, K. Aldape, E. Sulman, M. Bredel, M. Hegi, M. Gilbert, W. Curran, M. Werner-Wasik, M. Mehta</i>	431
003 Epigenetic Silencing of Hsa-miR-137 Contributes to Prostate Cancer Recurrence by Contributing to Over-expression of the Lysine Specific Demethylase 1 (KDM1a) <i>N. Mongan, E.M. Nilsson, A. McWilliam, M. Downes</i>	432
004 Identification of the BRAF-like Signature Predictive of Response Towards MEK Inhibition by Pimasertib (MSC1936369B) in Colorectal Cancer Cell Lines <i>V. De Vriendt, K. Sikora, B. Van den Bosch, V. Popovici, M. Delorenzi, S. Tejpar</i>	433
005 A Poor Predictor in Ovarian Cancer Patients Treated with Taxane–Platinum Regimen <i>A. Felisiak-Golabek, A. Rembiszewska, L. Szafron, J. Chodzynska, E. Kwiatkowska, I. Rzepecka, A. Dansonka-Mieszkowska, A. Podgorska, J. Kupryjanczyk</i>	434
006 Fully Automated and Single-Molecule Quantitative in Situ Hybridization for Histopathological Visualization of RNA Biomarkers <i>K. Wilkens, S. Bui, H. Wang, X.J. Ma, Y. Luo</i>	435
007 Interleukin-8 (IL8) and Transforming Growth-Factor Beta (TGF- $\beta$ ) as Drugable Biomarkers of Response, Progression-free (PFS) and Overall Survival (OS) with Pazopanib (PZP): a Phase II Study in Relapsed Urothelial Cancer (UC) <i>A. Necchi, N. Zaffaroni, L. Mariani, P. Giannatempo, N. Nicolai, M. Pennati, M.G. Daidone, A.M. Gianni, F.G. De Braud, R. Salvioni</i>	436
008 Biomarker Development for the Pharmacodynamic Assessment of CC-223, a Potent and Selective mTOR Kinase Inhibitor, in Phase I Clinical Trials <i>L. Wong, Y. Liu, X. Wu, D. Bauer, B. Chen, K. Hege, R. Chopra, J. Bendell, P. Munster, S. Xu</i>	437
009 Identification of Gene Expression Signature to Predict Anti-tumor Efficacy of MET/VEGFR Inhibitor, TAS-115 <i>H. Itadani, S. Hasako, K. Yonekura, A. Ooyama, H. Fujita, S. Oie, H. Hirai, S. Mizuarai, T. Utsugi</i>	438

- 010 Comparison of Dielectrophoretic Field Flow Fractionation (DEP-FFF) with ApoStream™, an Antibody Independent Platform, with Immunomagnetic Capture Using CellSearch™ for Enumeration of Circulating Tumor Cells in Patients with Metastatic Prostate Cancer 439  
*A. Poklepovic, D. Davis, V. Melnikova, K. Anderes*
- 011 Screening of Surface Markers Revealed That CD24 is Overexpressed in Malignant Pleural Effusions and is Required for Xenograft Tumor Formation 440  
*X. Yao, M. Labelle, C.R. Lamb, J.M. Dugan, C.A. Williamson, R.O. Hynes, K.D. Kittrup*
- 012 Quality Assurance of Biomarker Assays in Clinical Trials 441  
*J.A. Hall, R. Salgado, G.J. Peters, J.W.M. Martens, S. Sleijfer, D. Lacombe, N. Harbeck, M.G. Daidone, F.C.G.J. Sweep*
- 013 Gene Expression Changes in Response to a Panel of HER2 Tyrosine Kinase Inhibitors Indicate Potential Markers of Response in Breast Cancer Cell Lines 442  
*F. O'Neill, S. Aherne, S. Madden, M. Clynes, J. Crown, P. Doolan, R. O'Connor*
- 014 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy 443  
*H. Shao, J. Chung, L. Balaj, A. Charest, D.D. Bigner, B.S. Carter, F.H. Hochberg, X.O. Breakefield, R. Weissleder, H. Lee*
- 015 DNA Methylation-Based as a Prediction of Therapeutic Outcome in Serum of Patients with Breast Cancer 444  
*J. Martínez-Galan, J.R. Delgado, B. Torres-Torres, J. López-Peñalver, R. Del Moral, M. Ruiz de Almodóvar*
- 016 MicroRNA and Protein Expression in Breast Cancer FFPE Samples 445  
*A. Gámez-Pozo, I. Sánchez-Navarro, C.A. Castaneda, N. Ibarz Ferrer, G. de Velasco, F. García Martínez, E. Ciruelos, J.A. Fresno Vara*
- 017 Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer 446  
*W.S. Kim, S.Y. Lee, S.Y. Oh, H.J. Kim, K.Y. Lee*
- 018 14-3-3sigma Protein Expression and Its Predictive Value in Ovarian Cancer 447  
*A. Podgorska, A. Felisiak-Golabek, A. Rembiszewska, L. Szafron, J. Kupryjanczyk*
- 019 Activation of a Specific Metabolic Pathway May Distinguish Aggressive From Indolent Prostate Cancer 448  
*W. Huang, P.A. Young, K.W. Eliceiri, G. Wilding, H.S. Basu*
- 020 Molecular and Therapeutic Characterization of 25 Patient Derived Lung Cancer Tumorgrafts and Analysis for Response Markers to Targeted Therapies as Part of a Systems Biological Approach (PREDICT) 449  
*J. Rolff, M. Becker, R. Yildirimman, M. Isau, H. Hülsmann, R. Kuner, O. Politz, J. Merk, R. Herwig, I. Fichtner*
- 021 Non-invasive Absolute Quantification of EGFR Activating Mutation L858R and Gatekeeper Mutation T790M in NSCLC Plasma Samples Using Droplet Digital PCR 450  
*J. Kristof, S. Sankar, E. Bruening, S. Wong*
- 022 Two Insulin Receptor Isoforms Confer Intrinsic Resistance to the Antibody Against Insulin-like Growth Factor Receptor I 451  
*A. Forest, M. Amatulli, C. Damoci, D. Ludwig, N. Baltes, H. Fiebig, P. Houghton, M. Smith, L. Benjamin, R. Novosyadlyy*
- 023 Preclinical Pharmacokinetics, Radiation Dosimetry and Toxicity of <sup>111</sup>In-BzDTPA-pertuzumab, an Agent for Imaging Early Response to Trastuzumab in Breast Cancer Patients 452  
*K. Lam, C. Chan, D.A. Scollard, R.M. Reilly*
- 024 [F-18] Fluorothymidine (FLT) PET Imaging of Response of Acute Myeloid Leukemia to Chemotherapy 453  
*J.F. Eary, J.M. Link, M. Muzi, E. Estey, K. Kauno, K.A. Krohn*
- 025 AS1411 as a Potential Anti-Cancer Reagent for Treatment of Hepatocellular Carcinoma 454  
*T. Trinh, K. Safah, W. Tan, C. Liu*
- 026 Role of Hypoxia Imaging with [F-18]FMISO-PET and BOLD-MRI in Clinical Trials 455  
*K.A. Krohn, M. Muzi, J.M. Link, T.L. Richards, J.R. Fink, J.K. Rockhill, J.F. Eary*
- 027 FES PET is an Imaging Biomarker of Pharmacodynamic Response to Estrogen Receptor (ER) Modulating Therapies in Breast Cancer 456  
*K.A. Krohn, H.M. Linden, B.F. Kurland, J.M. Specht, V.K. Gadi, L.M. Peterson, E.K. Schubert, J.M. Link, D.A. Mankoff, J.F. Eary*



028	Actionable Mutations in Circulating Tumor DNA and Response to Target-based Therapies <i>F. Janku, P. Angenendt, S. Fu, G.S. Falchook, D.S. Hong, A. Naing, A.M. Tsimberidou, J.J. Wheler, F. Diehl, R. Kurzrock</i>	457
029	Hypoxia-inducible Factor 1a (HIF-1a) Induces Epithelial-mesenchymal Transition (EMT) in Thyroid Cancer Cell Lines <i>Y. Koh, H. Byeon, W. Kim, H. Hong, J. Kim, E. Choi, Y. Yang, H. Na</i>	458
030	Interferon Regulatory Factor-1 (IRF1) Protein Expression is Upregulated in Breast Cancer Tissue Microarrays with BRCA1 Mutations <i>J.L. Schwartz, R.B. Riggins, B.R. Haddad, M. Axelrod, A.N. Shajahan, R. Clarke</i>	459
031	Proteomic Insights in Oncology: What Have We Learned From Measuring Millions of Proteins? <i>R. Ostroff, M. Mehan, E. Brody, A. Stewart, S. Williams, A. Baron, W. Feser, W. Franklin, H. Wolf, Y. Miller</i>	460
032	Identification of Personalized Therapeutic Strategies and Associated Biomarkers in Adult Acute Myeloid Leukemia Using a Functional Drug Sensitivity and Resistance Testing Platform <i>T. Pemovska, B. Yadav, E. Kuleskiy, M. Kontro, C. Heckman, J. Knowles, K. Porkka, T. Aittokallio, O. Kallioniemi, K. Wennerberg</i>	461
033	Clinical Utility of a Highly Sensitive Blood BRAF Assay in Patients with Stage II and III Malignant Melanoma <i>R. Sullivan, L. Montaser, A. Sepehr, E. Buchbinder, A. Gunturi, R. Simonson, J.W. Mier, K.T. Flaherty, A.J. Iafrate, D.J. Panka</i>	462
034	The Comparison of the Cobas <sup>®</sup> KRAS Mutation Test and the High Resolution Melt Curve Analysis with Reflex Typing by Sanger Sequencing Method for Detecting KRAS Mutations in Formalin-fixed Paraffin-embedded Tissue Specimens of Colorectal Cancer <i>E. Schuurung, I. Platteel, E. van der Logt, L. Slagter-Menkema, S. Brouwer, E. Geuken, C. Weggemans, H. Sietsma, R. Kibbelaar, P.H. Kluin</i>	463
035	Imaging Gold Nanoparticles in a Novel Tissue Engineered 3D in Vitro Cancer Model <i>K. Ricketts, A. Nyga, C. Guazzoni, A. Castoldi, T. Magdeldin, G. Montemurro, H. Welch, U. Cheema, G. Royle, M. Loizidou</i>	464
036	SGI-110, a Novel Second Generation DNα Hypomethylating Agent, Enhances Sorafenib Activity and Alters Methylation Signature of HCC Cell Lines <i>S. Jueliger, J. Lyons, M. Azab, P. Taverna</i>	465
037	K-ras and Aryl Hydrocarbon Receptor Expression in Triple Negative Breast Cancers <i>J. Lee, W. Kim, W. Lee, J. Lee</i>	466
038	Different KRAS Mutations Confer Different Sensitivity to Cisplatin in Non Small Cell Lung Cancer <i>M. Marabese, E. Caiola, P. Rusconi, S. Piva, M. Garassino, G. Farina, M. Broggin</i>	467
039	Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma <i>L. Sigalotti, E. Fratta, G. Parisi, A. Couvre, P. Sonego, A. Rizzo, F. Colizzi, S. Coral, S. Massarut, M. Maio</i>	468
040	E-cadherin Expression Predicts Response of Carcinomas to Treatment with PTK2 Inhibitors <i>U.A. Hirt, C. Haslinger, N. Schweifer, P. Garin-Chesa, G.R. Adolf</i>	469
041	Identification of Patient-derived Tumor Xenografts Carrying Amplified Receptor Tyrosine Kinase Genes: Implications for Target-directed Therapies <i>A. Ackermann, J. Virayah, R. Krumbach, A. Maier, F. Foucault, T. Giesemann, T. Metz, V. Vuaroqueaux, H.H. Fiebig</i>	470
042	KRAS, BRAF and PIK3Ca Mutations as Predictors of Outcome From Maintenance Therapy with Bevacizumab with or Without Erlotinib After First Line Combination Therapy for Metastatic Colorectal Cancer: Results of the Phase III ACT Trial NCT00598156 Translational Study <i>K.G. Spindler, R. dePont Christensen, R.F. Andersen, N. Pallisgaard, A. Johnson, A. Jakobsen</i>	471
043	A Biomarker Study of Poly(ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 Activity On Ex Vivo Tissue From Ovarian Cancer Patients <i>J. Weberpals, X. Ma, J. Dimitroulakos, B. Djordjevic, K. Lapointe-Milot, N. Al Mutairi, L. Pelletier, A. Oza, J. Squire</i>	472
044	Evaluation of the Relation Specific PR Biomarkers to the Preclinical Activity of Onapristone <i>G. Serin, E. Gilles, A. Zukiwski</i>	473

- 045 Multiplexed Mutational Profiling in Japanese Patients with Thoracic Malignancies for Personalized Cancer Therapy 474  
*M. Serizawa, Y. Koh, H. Kenmotsu, M. Isaka, A. Naruoka, M. Endo, T. Nakajima, Y. Ode, T. Takahashi, N. Yamamoto*
- 046 Differences in Gene Expression Between Androgen Receptor Positive and Negative Triple Negative (ER/PR/Her2) Breast Carcinomas 475  
*A. Ghazalpour, G. Basu, R. Bender, Z. Gatalica*
- 047 Serum Proteomic Classification in Refractory Non-small-cell Lung Cancer Treated with Erlotinib +/- Pazopanib in a Randomized Placebo-controlled Phase II Study 476  
*D.R. Spigel, H.A. Burris, F.A. Greco, A.J. Lipman, D.M. Waterhouse, D.B. Daniel, Z. Ma, H.T. Arkenau, J. Grigorieva, J.D. Hainsworth*
- 048 pERK Expression in Erlotinib-treated Patients with Advanced Pancreatic Cancer: a Translational Subgroup Analysis From the Randomized AIO-PK0104 Phase III Trial 477  
*S. Boeck, S. Ormanns, R.P. Laubender, A. Jung, J.T. Siveke, M. Haas, T. Kirchner, V. Heinemann*
- 049 Prognostic Significance of pAKT Plus Estrogen Receptor Status in Adjuvant Cytotoxic Treatment of Breast Cancer 478  
*S.X. Yang, K. Kidwell, J.C. Costantino, E.P. Mamounas, D. Nguyen, C. Kim, N. Wolmark, S. Paik*
- 050 Plasma is Superior to Serum for CfDNA Mutation Detection and Monitoring 479  
*R.F. Andersen, K.G. Spindler, A. Jakobsen, N. Pallisgaard*
- 051 Detection by Immunohistochemistry of Prostate Stem Cell Antigen (PSCA) in Tumors is Not a Predictive Biomarker for the Anti-PSCa Monoclonal Antibody AGS-1C4D4: Identification of Alternative Predictive Biomarkers 480  
*F. Doñate, A. Hartford, K. Morrison, L. da Cruz, J. Nater, T. Brooks, J. Ou, P. Chalita-Eid, D. Stover, L. Reyno*
- 052 Osteopontin Overexpression Synergistically Interacts with Aurora A Overexpression, and is Associated with Tumor Progression, Early Tumor Recurrence, and Poor Prognosis in Hepatocellular Carcinoma 481  
*Z. Lin, H. Pan, N. Sun, Y. Jeng, A. Cheng, H. Hsu*
- 053 Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib 482  
*H. Zahir, S. Rodig, L.V. Sequist, L. Rimassa, C. Eng, A.B. Halim, Y. Wang, R. von Roemeling, Y. Chen, B. Schwartz*
- 054 Development of a Quantitative Colorectal Cancer SRM Assay for Use in FFPE Tumor Tissues 483  
*T. Hembrough, L. Henderson, P. Xu, W.L. Liao, J. Burrows, D.V.T. Catenacci*
- 055 Germline Variants in Angiogenesis Genes as Markers of Progression-free Survival in Stage I-III Non-small Cell Lung Cancer Patients 484  
*F. Innocenti, K. Owzar, C. Jiang, D. Crona, A. Etheridge, J. Jassem, W. Rzyman, F.R. Hirsch, R. Dziadziuszko, D.M. Glubb*
- 056 Targeting the MAP Kinase and Wnt Signaling Pathways in Preclinical Models of Colorectal Cancer 485  
*A. Spreafico, P.J. Klauck, J.J. Tentler, T.M. Pitts, A.C. Tan, J. Kim, M.A. Gregory, M.C. McManus, J.J. Arcaroli*
- 057 Carnitine Palmitoyltransferase 1C (CPT1C) as Novel Key Regulator of Cancer Metabolism and Carcinogenesis 486  
*N. Sanchez-Macedo, J. Feng, E. Lucchinetti, T.W. Mak, K. Zaugg*
- 058 Evaluation of Predictive Biomarkers for the Antineoplastic Effect of TAK-733, a Novel Investigational Allosteric Inhibitor of MEK1/2 487  
*E. Gangolli, D. Blair, M. Schu, C. Szynal, J. Ecsedy, A. Hori, A. Dorner, J. Bolen, P. Vincent, A. Chakravarty*
- 059 A Combination of Surrogate and Tumor Biopsy Biomarker Data Demonstrates JAK Pathway Inhibition by AZD1480 in Phase I Patient Samples 488  
*P. McCoon, J.P. Eder, D. Huszar, K. McEachern, P. Schroeder, W. Tang, C. Womack, Y.K. Kang, S.G. Eckhardt*
- 060 Enzastaurin (LY317615.HCl) and Its Primary Metabolite (LY326020.HCl) Exert Antitumor Effects in Diffuse Large B Cell Lymphoma Through Multiple Mechanisms, Most Notably Control of 4EBP1 Activity 489  
*J. Graff, A.M. McNulty, C. Dumstorf, S. Parsons, B.W. Konicek, C. Hall*

061	Detection and Genomic Interrogation of Circulating Tumor Cells (CTCs) and Circulating Tumor Stem Cells (CTSCs) From Men with Metastatic Castration-resistant Prostate Cancer (mCRPC) <i>T. Friedlander, V. Ngo, S. Doty, Q. Zhao, H. Dong, C. Ryan, W. Chen, P. Paris</i>	490
062	Generation of Patient-Derived Tumor Xenografts Genetic Identity Cards to Couple Tumor Heterogeneity and Individual Response to Treatments <i>S. Cairo, A. Beurdeley, V. Yvonnet, O. Déas, M.F. Poupon, J.G. Judde</i>	491
063	Frequency and Co-occurrence of MAPK and PI3K Pathway Driver Mutations to Guide Single-agent and Combination Therapies: an Analysis of Next Generation Sequence Data From 2700 Patients <i>E.T. Bowden, P. Wyngaard, N.A. Khazanov, S. Eddy, M. Tomilo, P. Williams, S. Sadis, D.R. Rhodes</i>	492
064	Creating Clinical Target Validation Groups Via Quality Assured Transfer of Robust Clinical Pharmacodynamic (PD) Assays From the National Cancer Institute <i>R.E. Parchment, R.J. Kinders, J. Ji, A.K. Srivastava, K. Ferry-Galow, J.E. Tomaszewski, J.H. Doroshow</i>	493
065	Novel Prognostic and Predictive Germline Genetic Markers of Overall Survival in Renal Cell Carcinoma Patients Treated with Sorafenib <i>D. Crona, A. Skol, H. Ahsan, C. Pena, F. Innocenti</i>	494
066	The PI3K/mTOR Inhibitor GDC-0980 Demonstrates Target Engagement and Pathway Modulation in Tumor Tissue at Tolerated Doses <i>Y. Yan, J. Spoerke, J. Wu, R. Desai, H. Koeppe, G. Hampton, J. Fredrickson, M. Derynck, J. Lauchle, M. Lackner</i>	495

### **Bioreductive Agents**

Poster board		Abstract number
067	Targeting NQO1 as a Potential Anticancer Strategy Using the Small Molecule Deoxyxyboquinone <i>E.I. Parkinson, J.S. Bair, E.A. Bey, D.A. Boothman, P.J. Hergenrother</i>	496

### **New Molecular Targets**

Poster board		Abstract number
068	Analysis of the Level of Carbohydrates and Nucleotide Metabolic Enzymes and the Receptor Status of the Tumor <i>I. Zinkovych, I. Sedakov</i>	497
070	Clinical Application of Automation of Phage Display and SELEX Technology, the Basis for the Development of Targeted Therapeutics <i>M. Nabil, M. Alzaza</i>	499
071	Voltage-gated Sodium Channel as Potential Target for Metastatic Breast Cancer: Anti-invasive Effects of Commonly Used Blockers <i>N.F. Mokhtar, M.B.A. Djamgoz</i>	500
072	Jab1/CSN5 as a Novel Target to Overcome the Resistance to Trastuzumab in Her2-positive Breast Cancer <i>T. Vu, Q. Zhang, L. Tian, T. Shackelford, T. Kute, F.X. Claret</i>	501
073	Preclinical Pharmacokinetics and Efficacy Assessment of a Potent and Selective MEK Inhibitor, GDC-0623 <i>E. Choo, M. Belvin, M. Merchant, E. Chan, P. Hollingshead, C. Orr, J. Boggs, E. Plise, K. Robarge, M. Zak</i>	502
074	TRPV4 Channels in Basal-like Breast Cancer Cells <i>S.Y.N. Jamaludin, F.M. Davis, A.A. Peters, T.J. Gonda, S.J. Roberts-Thomson, G.R. Monteith</i>	503
075	Role of Hypoxia-induced Epithelial-Mesenchymal Transition in Calcium Signalling in Breast Cancer Cells <i>I. Azimi, H. Beilby, F.M. Davis, S.J. Roberts-Thomson, G.R. Monteith</i>	504
076	Two-Pore Channels in Breast Cancer Cells <i>A.H. Jahidin, F.M. Davis, S.J. Roberts-Thomson, G.R. Monteith</i>	505
077	RAS-synthetic-lethal Compounds Induce Lipoxygenase-dependent Cell Death <i>W.S. Yang, M. Welsch, K. Shimada, C.B. Clish, R. SriRamaratnam, B.R. Stockwell</i>	506
078	Regulation of Hyaluronidase1 Enzymatic Activity by C-mannosylation <i>Y. Goto, Y. Niwa, T. Suzuki, N. Dohmae, K. Umezawa, S. Simizu</i>	507
079	In Vitro Selection of Molecular Recognition Elements for Molecular Targeting of Prostate Cancer <i>R. Williams, S. Nayeem, L.J. Sooter</i>	508

080	Transcriptome Analysis Reveals Candidate Genes and Pathways Regulated by TNFAIP8, A NF- $\kappa$ B-inducible Oncogenic Molecule, in Androgen-refractory Metastatic Prostate Cancer Cells <i>T. Day, X. Li, X. Zou, H. Resson, U. Kasid</i>	509
081	Y-box Binding Protein-1 as a Molecular Target for Potentiating Chemotherapeutic Drugs <i>B.H. Bay, Y. Yu, I. Inoue, T. Guo, C.T. Ng, J.Y. Wong, K. Matsumoto, G.W.Y. Yip</i>	510
082	Identification of a Small Molecule (PTC596) That Preferentially Depletes Tumor Stem Cells by Reducing Levels of Functional BMI1 Protein <i>T.W. Davis, S. Lee, M. Dumble, N. Sydorenko, R. Baiazitov, S. Jung, J. Sheedy, M. Weetall, Y.C. Moon, L.X. Cao</i>	511
083	Identification of FER as a New Molecular Target in Non-small Cell Lung Cancer <i>M. Kawakami, M. Sunohara, Y. Amano, R. Ishikawa, K. Watanabe, E. Hamano, N. Ohishi, T. Nagase, Y. Yatomi, D. Takai</i>	512
084	Development of a Novel Inhibitor of ADP-Ribosylation Factor 1 (Arf1) That Has Potential for Cancer Therapy <i>Y. Ohashi, H. Iijima, N. Yamaotsu, K. Yamazaki, M. Okamura, K. Sugimoto, S. Hirono, S. Dan, T. Yamori</i>	513
085	The Discovery of CGEN-15001T, a Novel Immune Checkpoint Target for Immunotherapy in Cancer <i>G. Cojocar, Z. Levine, A. Toporik, L. Dassa, S. Nemzer, O. Levy</i>	514
086	Superior Efficacy of Co-treatment with NPM1 Antagonist and FLT3 Inhibitor or Pan-histone Deacetylase Inhibitor Against Cultured and Primary Human AML Cells Co-expressing Mutant NPM1 and FLT3-ITD <i>R. Balusu, N. Huffman, W. Fiskus, J. Smith, K. Peth, S. Hembruff, R. Rao, S. Ganguly, J. McGuirk, K.N. Bhalla</i>	515
087	Development of Selective PIM Kinase Inhibitors for Cancer Treatment <i>K. Brzozka, R. Windak, K. Prymula, M. Milik, A. Klosowska, J. Fogt, A. Bialas, K. Krawczynska, M. Galezowski, W. Czardybon</i>	516
088	NMS-P153, a Tight-Binder Inhibitor of the Spindle Assembly Checkpoint Kinase MPS1 <i>R. Colombo, M. Caldarelli, M.L. Giorgini, O. Milani, N. Avanzi, F. Sola, E. Pesenti, D. Donati, A. Galvani</i>	517
089	Development of Selective CDK8 Inhibitors for Colorectal Cancer Treatment <i>K. Brzozka, A. Zarebski, R. Windak, K. Krawczynska, A. Klosowska, A. Dreas, J. Fogt, M. Cholody, M. Milik, T. Rzymiski</i>	518
090	HIF1A Knockdown Decreases Cell Proliferation in Medulloblastoma Cell Line Under Hypoxic Conditions <i>G. Alencastro Veiga Cruzeiro, V.S. Silveira, A.F. Andrade, V.K. Suazo, L.G. Tone, C.A. Scrideli, E.T. Valera</i>	519
091	An Oral Formulation of YK-4-279 Effective in Xenograft Models of Ewing Sarcoma <i>J. Ludwig, S. Lamhamedi Cherradi, K. Culotta, D. Doolittle, R. Aiyer, J. O'Dorisio</i>	520
092	Cell Cycle Regulation Changes in Drug-Resistant Cancers <i>N. Mohd Safiwan, T. Crook, H. Coley</i>	521
093	Preclinical Evaluation of Indium 111 Radiolabeled Trastuzumab and Pertuzumab for HER2-positive Breast Cancer Molecular Imaging <i>A. Oudot, B. Collin, O. Raguin, M. Moreau, J.M. Vrigneaud, O. Duchamp, N. Varoquaux, F. Denat, F. Brunotte, P. Fumoleau</i>	522
094	Biological Effects of Ruthenium and Osmium Nitrosyl Complexes with Azole Heterocycles <i>M.S. Novak, G. Büchel, A. Gavriluta, J.B. Tommasino, D. Luneau, M.A. Jakupec, V.B. Arion, B.K. Keppler</i>	523
095	LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer <i>S. Maubant, V. Maire, B. Tesson, D. Gentien, B. Marty-Prouvost, F. Cruzalegui, S. Depil, G.C. Tucker, S. Roman-Roman, T. Dubois</i>	524
096	HDAC6 Inhibitor C1A Synergizes with BEZ-235 in Colon Cancer Cells in Vitro and Potently Inhibits Tumor Growth in Vivo <i>M. Kaliszczak, S. Trousil, O. Åberg, M. Perumal, Q.D. Nguyen, E.O. Aboagye</i>	525
097	Tumour Suppressor Merlin Regulates Thrombospondin 1 Signalling Via CD47 <i>M. Barczyk, L. Zhou, N. Avent, O. Hanemann</i>	526
098	ADAM17 as a Therapeutic Target for the Treatment of Breast Cancer: Preclinical Studies with an Inhibitory Monoclonal Antibody <i>F. Caiazza, G. Murphy, P.M. McGowan, J. Crown, M.J. Duffy</i>	527

099	The BRD-inhibitor OTX015 Shows Pre-clinical Activity in Diffuse Large B-cell Lymphoma (DLBCL) <i>P. Bonetti, M. Ponzoni, M.G. Tibiletti, A. Stathis, P. Heirat, E. Zucca, F. Bertoni</i>	528
100	Targeting SIRT1 Activity: a Novel Strategy for Acute Myeloid Leukemia Therapy <i>S.T. Nawrocki, K.R. Kelly, C.M. Espitia, C. Bachier, W.G. Bornmann, J.S. Carew</i>	529
101	Chk1 Inhibitor Targets Replicative Stress in Melanomas <i>B. Gabrielli, K. Brooks, V. Oakes, B. Edwards, J. Chen, P. Mukhopadhyay</i>	530
102	Calcium Channel Transient Receptor Potential V6 (TRPV6) as a Potential Therapeutic Target for Some Breast Cancers <i>A.A. Peters, P.T. Simpson, J.J. Bassett, J.M. Lee, S. Song, M.O. Parat, S.R. Lakhani, P.A. Kenny, S.J. Roberts-Thomson, G.R. Monteith</i>	531
103	Glucose-6-phosphate Dehydrogenase Inhibition and Its Effects On the Radiosensitization of Head and Neck Squamous Carcinoma Cells <i>G.V. Hopkins, D.I. James, M.J. Cockerill, H.F. Small, I.D. Waddell, D.J. Ogilvie</i>	532
104	Dysregulation of Beta-catenin Pathway by JCV T-Antigen in Colon Cancer <i>M.J. Ripple, A.P. Struckhoff, R. McGoey, L. Del Valle</i>	533
105	CHEK1 Cooperates with IKK $\epsilon$ to Promote Survival of Ovarian Cancer Patients <i>M. Kim, C. Annunziata</i>	534
106	Non Coding Mitochondrial RNAs as Novel Teragnostic Molecular Tool in Cervix Cancer <i>J. Villegas, R. Avila, K. Dadlani, M. Socias, L. Zapata, C. Villota, V. Burzio, L. Oliveira-Cruz, E. Bustamante, L.O. Burzio</i>	535
107	Determining the Likelihood of Achieving Clinical Proof-of-Mechanism (PoM) with AZD1208 From Preclinical Efficacy Studies Using PK/PD Modelling <i>F. Gibbons, K. McEachern, E. Keeton, D. Huszar</i>	536
108	Reovirus Therapy Induces Endoplasmic Reticular Stress and Apoptosis in RAS-activated Pancreatic Cancer <i>J.S. Carew, C.M. Espitia, K.R. Kelly, M. Coffey, J.W. Freeman, S.T. Nawrocki</i>	537
109	Finding New Signalling Pathways That Contribute to Cancer Pathogenesis <i>I.J. Majewski, Z. Xue, L. Mittempergher, M. Michaut, R. Kluin, J. Peeters, A. Bosma, E. Leproust, L.F. Wessels, R. Bernards</i>	538
110	BET Bromodomain Inhibition Targets Both c-Myc and IL7R in Acute Lymphoblastic Leukemia <i>C. Ott, N. Kopp, L. Bird, R. Paranal, J. Qi, T. Bowman, S. Rodig, A. Kung, D. Weinstock, J. Bradner</i>	539
111	Regulation and Function of the Nek11 Kinase in Colorectal Cancer <i>S.R. Sabir, N.K. Sahota, G.D. Jones, A.M. Fry</i>	540
112	The Histone Methyltransferase EZH2 is Required for Cell Growth in Diffuse Large B-cell Lymphoma <i>P. Trojer, S. Garapaty, F. Lan, V. Balsubramanian, E. Chan, C. Hatton, R. Campbell, R. Cummings, E. Normant, B. Bryant</i>	541
113	The Experimental Anti-cancer Drug Mitochondrially-targeted Vitamin E Succinate Inhibits Mitochondrial Transcription <i>J. Rohlena, J. Truksa, L. Dong, M. Vondrusova, K. Kluckova, J. Neuzil</i>	542
114	Overexpression of Discoidin Domain Receptor 1 (DDR1) in Oral Squamous Cell Carcinoma <i>W.H. Tsai, Y.L. Chen, H.C. Chen, A.J. Cheng, K.Y. Chang, P.Y. Chu, J.R. Hsiao, J.Y. Chang, S.F. Lin</i>	543
115	Characterization of Potent and Well Tolerated Second Generation FLT3 Inhibitors <i>M. Ciomei, N. Amboldi, S. Crioli, D. Donati, I. Fraietta, A. Galvani, C. Nuccio, E. Pesenti, G. Texido Romero, A. Lombardi Borgia</i>	544
116	DHT Regulates Serum Response Factor Transcription Activity in Castrate-resistant Prostate Cancer Cell Lines <i>M. Prencipe, A. O'Neill, G. O'Hurley, H. Klocker, E.W. Kay, W.R. Watson</i>	545
117	ER Stress is an Additional Molecular Target for Triapine and Its Dimethylated Derivative <i>R. Trondl, P. Heffeter, C.R. Kowol, M.A. Jakupec, W. Berger, B.K. Keppler</i>	546
118	Novel Targets for Monoclonal Antibody Therapy <i>R. Grifantini, P. Pileri, A. Grandi, M. Parri, S. Campagnoli, I. Naldi, C. Cinti, G. Grandi, G. Viale, P. Sarmientos</i>	547
119	Inhibition of Glioblastoma Cells Proliferation by Fenretinide Goes Through STAT3 Pathway <i>A. Gasperi Campani, F. Pancotti, L. Roncuzzi</i>	548
120	Down-regulation of Caveolin-1 Mediated Either by Caveolin-1 Silencing or by Fenretinide Causes Inhibition of Osteosarcoma Cells Proliferation <i>A. Gasperi Campani, F. Pancotti, L. Roncuzzi</i>	549

- 121 The Tumour-specific Antigen TRIM28 is an Independent Prognostic Marker in Colorectal Cancer 550  
*S. Fitzgerald, K.M. Sheehan, A. O’Grady, D. Kenny, R. O’Kennedy, E.W. Kay, G. Kijanka*
- 122 The Role of the Hedgehog Signalling Pathway in the Tumour Microenvironment of Pancreatic Cancer 551  
*F. Saini, R. Argent, A. Grabowska*
- 123 Comprehensive Genomic Profiling of Small Cell Lung Cancer Reveals SOX2 Amplification and MYCL1 Rearrangements 552  
*C.M. Rudin, S. Durinck, E. Stawiski, J.T. Poirier, Z. Modrusan, E.A. Bergbower, P.B. Illei, M. Varella-Garcia, J.D. Minna, S. Seshagiri*
- 124 A Chemical Systems Biological Approach to Understand the Association of Metabolic Stress and Resistance to DNA Damaging Drugs in Breast Cancer 553  
*M.M. Majumder, S.A. Khan, A. Lehto, L. Turunen, S. Kaski, K. Wennerberg*
- 125 Identification of Synthetic Lethal Interactions with Oncogenic Ras Through Large Scale Functional Genomic Screening 554  
*R.L. Beijersbergen, J. Vidal-Rodriguez, C. Lieftink, K. De Lint, J. Poell, P. Halonen, B. Morris, K. Jastrzebski, W.A.B.E. Nijkamp, H.J. Kuiken*
- 126 A Study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma 555  
*D. Mahalingam, Y. Wang, T.W. Lu, J. Sarantopoulos, S. Vemulapalli, S. Aparo, M. Coffey, G. Gill, G. Kennealey, M. Mita*
- 127 Antineoplastic Effects of DHMEQ and Its Chemo- and Radio-sensitizing Potential in Pediatric Medulloblastoma Cells 556  
*P.M.M. Ramos, A.M. Castro-Gamero, J.A. Pezuk, H.F. Oliveira, K. Umezawa, C.A. Scrideli, L.G. Tone*
- 128 PRMT5, a Novel Epigenetic Target in Lung Cancers 557  
*G.A. Otterson, X. Wu, M. Welliver, S. Sharma, K. Shilo, C. Hitchcock, C. Li, R. Baiocchi*
- 129 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer 558  
*M. Mullooly, N. O’Brien, R.S. Finn, D.J. Slamon, J. Crown, P.M. McGowan, M.J. Duffy*
- 130 ERBB4 is a Therapeutic Target in Melanoma Resistant to Braf Inhibitors 559  
*C.M. Amato, L.J. Su, S.E. Robinson, R.T. Gonzalez, W.A. Robinson*
- 131 Receptor Tyrosine Kinase Profiles and Human Papillomavirus Status in Oropharyngeal Squamous Cell Carcinoma 560  
*F. Perrone, B. Cortelazzi, A. Gloghini, P. Bossi, A.V. Gualeni, L. Licitra, S. Pilotti*
- 132 Development of a Quantitative Gastroesophageal Cancer Selected Reaction Monitoring Mass Spectrometric Multiplex Assay for Use in FFPE Tumor Tissues 561  
*D. Catenacci, P. Xu, L. Henderson, W. Liao, J. Burrows, T. Hembrough*
- 133 Antitumor Activity of the Polo-like Kinase (PLK) Inhibitor, TAK-960, Alone and in Combination with Standard Agents Against KRAS WT and MT Colorectal Cancer (CRC) Models 562  
*T. Pitts, K.L. McPhillips, H.M. Selby, A. Spreafico, S.M. Bagby, B.C. Britt, J.J. Tentler, A.C. Tan, K. Kuida, S.G. Eckhardt*
- 134 Ex Vivo Culture of Fresh Tumor Tissues From Patients Assessing Pharmacodynamic (PD) Markers of OTX008, a Novel Galectin-1 Inhibitor: Relevance to Phase I Trial 563  
*L. Astorgues-Xerri, M.e. Riveiro, A. Tijeras-raballand, N. Muller, K. Rezai, M. Albuquerque, V. Paradis, K. Noel, E. Raymond, S. Faivre*
- 135 Anti-tumour Activity of the Focal Adhesion Kinase Inhibitor GSK2256098C in Ovarian Cancer 564  
*D. Doughty Shenton, K. McLeod, M. Muir, A. Kinnaird, C. Gourley, N.O. Carragher, M.C. Frame, V.G. Brunton*
- 136 Targeting P38δ MAPK in Oesophageal Cancer: a Possible Future Therapeutic Goal? 565  
*C. O’Callaghan, L. Fanning, A. Houston, O.P. Barry*
- 137 Mechanisms of Resistance to MEK Inhibitor AZ6244 in KRAS Mutant Metastatic Colorectal Cancer 566  
*V. Gambino, C. Sun, A. Prahallad, A. Tzani, W. Grenrum, L. Mitterpergher, R. Bernards*
- 138 A Novel Focal Adhesion Kinase Inhibitor (PF-04554878) Decreases Growth and Induces Apoptosis in Pancreatic Neuroendocrine Tumor Cells 567  
*R. Francois, S. Lu, D. He, M. Zajac-Kaye, S. Hochwald*
- 139 Design of PTX008 That Allosterically Targets Galectin-1 to Inhibit Tumor Growth in Mice 568  
*R.P.M. Dings, J.I. Levine, L. Astorgues-Xerri, N. Kumar, M. Serova, J. MacDonald, E. Raymond, T.R. Hoyer, K.H. Mayo*

140	Prognostic Impact of Splicing Variants in Pediatric Brain Tumors: in Silico Analysis From High Density Microarrays <i>O. Pérez-Gonzalez, M. Macias-Vega, R. Cardenas-Cardos, A. Marhx-Bracho, R. Rivera-Luna</i>	569
141	MiR-124 Targets Androgen Receptor and Inhibits Tumorigenesis of Prostate Cancer Cells <i>R. de Vere White, X.B. Shi</i>	570
142	Targeting the GLUT1 Transporter as a Novel Therapeutic Approach to Exploit the Dependency of Cancer Cells On the “Warburg Effect” <i>D.A. Chan, P. Pearson, J.M. Vernier, S. Hershenson, J. Freddo, R. Tabibiazar, A.J. Giaccia, P.M. O’Connor</i>	571
143	Integrated Genomic Analysis Identifies Candidate Genes in Luminal B Breast Cancer <i>L. Addou-Klouche, S. Moulessehoul, D. Birnbaum, M. Chaffanet</i>	572
144	Sonic Hedgehog Pathway Activation Reveals Hexokinase-2-mediated Aerobic Glycolysis as a Novel Target for Medulloblastoma Therapy <i>T. Gershon, A. Crowther, A. Tikunov, I. Garcia, H. Yuan, J. Macdonald, M. Deshmukh</i>	573
145	FGFR1, a Significant Prognostic Factor in Muscle Invasive Bladder Cancer <i>S. Rha, S. Lim, M. Koh, H. Jeong, H. Kim, S. Lee, J. Ahn</i>	574
146	RAIDS: Rational Molecular Assessments and Innovative Drug Selection, an EU Funded Project <i>C. Kurzeder, S. Scholl, M. Kamal, E. Banu, G. Kenter, A. Mustea, C. Ngo, M. Popovic</i>	575
147	GLUT-1, CAIX and HKII Expression in Localized Cervical Carcinoma Patients Treated by Exclusive Radiotherapy and Concomitant Chemoradiotherapy <i>P. Moreno-Acosta, S. Schyrly Carrillo, O. Oscar Gamboa, J. Jineth Acosta, J. Joseph Balart Serra, N. Nicolas Magne, A. Alfredo Romero-Rojas</i>	576
148	Pharmacological Reactivation of Mutant p53 by PRIMA-1 Induces Apoptosis and Enhances Chemotherapeutic Cytotoxicity in Pancreatic Cancer Cells <i>P. Izetti, A. Hautefeuille, A.L. Abujamra, C. Brunetto de Farias, R. Roesler, G. Macedo, P. Hainaut, G. Lenz, A.B. Osvaldt, P. Ashton-Prolla</i>	577
149	High Content Analysis of the Epithelial-Mesenchymal Transition to Identify Novel Targets in Cancer Progression <i>S. Lamouille, R. Judson, R. Blleloch, R. Derynck</i>	578

### Phase 0, I and II

		Abstract number
	Poster board	
150	Phase I and Pharmacokinetic (PK) Study of Pazopanib in Combination with Two Schedules of Docetaxel (D) in Patients (pts) with Advanced Solid Tumors <i>P. Hamberg, R.H. Mathijssen, P. de Bruijn, D. van der Biessen, W.J. Loos, S. Sleijfer, J. Verweij, M.J. de Jonge</i>	579
151	First-in-human, Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Results From a Phase I Study of a Selective BRAF Inhibitor (BRAFi) RG7256 in Patients with BRAF V600-mutated Advanced Solid Tumors <i>R. Dienstmann, U. Lassen, J. Cebon, J. Desai, M.P. Brown, S. Evers, F. Su, W. Zhang, V. Meresse, J. Tabernero</i>	580
152	An Adaptive, 2-stage, Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients with Advanced Solid Tumors <i>F.E. Stuurman, M.P. Lolkema, P.M. Soetekouw, H. Rosing, M. Mergui-Roelvink, J.H. Beijnen, E.E. Voest, H. Van Tinteren, A.D.R. Huitema, J.H.M. Schellens</i>	581
153	Total and Non-liposome Associated (free) Muramyl Tripeptide-Phosphatidyl Ethanolamine (MTP-PE) Pharmacokinetics (PK) Following Intravenous (IV) Infusion of Liposomal Mifamurtide to Healthy Adults <i>K. Venkatakrishnan, Y. Liu, D. Noe, J. Mertz, C. Oliva, A. Milton</i>	582
154	Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Head and Neck Cancer. Preliminary Results of a Phase I/II Study <i>F. Perri, P. Muto, C. Schiavone, F. Ionna, C. Aversa, P. Maiolino, E. Cavalcant, F. Sandomenico, F. Caponigro</i>	583

- 155 Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors 584  
*W. Ma, C. Weekes, D.K. Pawaskar, G. Fetterly, W. Messersmith, G. Dy, R.M. Straubinger, W.J. Jusko, S.G. Eckhardt, A.A. Adjei*
- 156 First-in-man, Multicenter, Phase I Trial Evaluating the Safety of First-in-class Therapeutic, EGFR-targeted, Paclitaxel-Packaged Minicells 585  
*B. Solomon, J. Desai, A. Scott, M. Rosenthal, G. McArthur, D. Rischin, E. Segelov, J. MacDiarmid, H. Brambhatt*
- 157 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer 586  
*E. Calvo, N. Dickgreber, S. Hynes, R. Decker, E. Kumm, U. Ohnmacht, A. Bence, T. Wehler, M. Sebastian*
- 158 Phase I Dose-escalation Study of PF-04449913, an Oral Hedgehog Inhibitor in Patients with Select Solid Tumors 587  
*A. Wagner, W. Messersmith, N. Shaik, X. Zheng, K. McLachlan, R. Cesari, R. Courtney, W. Levin, A. El-Khoueiry*
- 159 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies 588  
*W.A. Messersmith, P.M. LoRusso, J.M. Cleary, A. Dasari, B. Huang, N.M. Shaik, R. Cesari, K.R. McLachlan, K.A. Kern, G.I. Shapiro*
- 160 Phase I, Open-Label, Cohort Study of CAVATAK (Coxsackievirus A21) Given Intravenously to Stage IV Patients Bearing ICAM-1 Expressing Solid Tumours 589  
*W. Liauw, B. Chern, D.R. Shafren*
- 161 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer 590  
*M. Voi, S. Fu, J. Nemunaitis, J. Bauman, A. Bessudo, O. Hamid, S. Witta, G. Dy, C. Lai, R. Laliberte*
- 162 Phase I Trial of Z-endoxifen with Estrogen Receptor Imaging in Adults with Refractory Hormone Receptor-positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors 591  
*S. Kummar, S.L. Safgren, M. Lindenberg, K. Kurdziel, J.M. Reid, H. Streicher, M.M. Ames, P. Jacobs, J. Collins, J.H. Doroshow*
- 163 First-in-human Phase 0 Trial of Oral 5-iodo-2-pyrimidinone-2'-deoxyribose (IPdR) in Patients with Advanced Malignancies 592  
*S. Kummar, L. Anderson, K. Hill, E. Majerova, D. Allen, Y. Horneffer, P. Ivy, P. Harris, J.H. Doroshow, J. Collins*
- 164 Pharmacokinetics (PK) and Pharmacodynamics (PD) of Liposomal Mifamurtide (L-MTP-PE) in Adult Volunteers with Mild and Moderate Hepatic Impairment (HI) 593  
*K. Venkatakrishnan, Y. Liu, D. Noe, J. Mertz, M. Mockler, T. Marbury, K. Farbakhsh, C. Oliva, A. Milton*
- 165 A Phase I Dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of LY2940680, an Oral Smo Inhibitor 594  
*J. Bendell, G. Weiss, J. Infante, R. Ramanathan, S. Jones, R. Korn, H. Burris, L. Brail, E. Jones, D. Von Hoff*
- 166 Effect of Ketoconazole On Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor 595  
*M. Cotreau, N. Siebers, L. Massmanian, A. Strahs, D. Vargo*
- 167 The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor 596  
*M. Cotreau, D. Subic, L. Massmanian, A. Strahs, D. Vargo*
- 168 Pharmacokinetics of the Novel FGFR and VEGFR Inhibitor, E-3810, in Patients with Advanced Solid Tumors Participating to a Phase I/II Trial 597  
*M. Zangarini, F. Sala, M.G. Camboni, R. Cereda, V. Livi, R. Bahleda, R. Dienstmann, A. Delmonte, M. D'Incalci, M. Zucchetti*
- 169 A Phase 1b Study of Demcizumab Plus Pemetrexed and Carboplatin in Patients with 1st Line Non-Small Cell Lung Cancer (NSCLC) 598  
*M. McKeage, D. Kotasek, M. Millward, B. Markman, M. Jameson, M. Hidalgo, D. Harris, R. Stagg, J. Dupont, B. Hughes*



- 170 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients 599  
*S. Slater, P.O. Witteveen, R. Plummer, R. Kristeleit, T.R.J. Evans, L. Reyderman, B. de las Heras, D. Verbel, B. Ink, J.H.M. Schellens*
- 171 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors 600  
*N. Houédé, J.P. Delord, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens, S. Rottey, R. Kefford, O. von Richter, E. Raymond*
- 172 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors 601  
*D. Mahalingam, G. Wilding, S. Denmeade, J. Sarantopoulos, D. Cosgrove, J. Cetnar, N. Azad, J. Bruce, M. Kurman, M. Carducci*
- 173 Evaluation of Elderly Patients (>70 Years Old) Enrolled in Phase I Clinical Trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center From 2009–2011 602  
*J. Rowe, S. Patel, M. Mazo-Canola, A. Parra, K. Kelly, S. Weitman, A. Karnad*
- 174 Phase II Trial of Oncolytic Reovirus in Combination with Chemotherapy in NSCLC Pts with Kras Activated Tumors 603  
*M. Villalona-Calero, E. Lam, G. Otterson, J. Zhao, M. Timmons, D. Subramaniam, E. Hade, G.M. Gill, M. Coffey, E. Bertino*
- 175 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial 604  
*A. Awada, J.P. Delord, N. Houédé, C. Lebbe, T. Lesimple, J.H.M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond*
- 176 A Phase 1, Open-label, Dose-escalation Study of Oral Administration of the Investigational Agent MLN0128 in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid Malignancies 605  
*H. Burris, L. Hart, C. Kurkjian, G. Berk, P. Lipman, C. Patel, C. Rommel, M. Martin, J. Infante*
- 177 Impact of Beta-blocker Medication in Patients with Platinum Sensitive Recurrent Ovarian Cancer – a Combined Analysis of 2 Prospective Multicenter Trials by the AGO Study Group, NCIC-CTG and EORTC-CTG 606  
*F. Heitz, A. du Bois, P. Harter, C. Kurzeder, D. Lubbe, I. Vergote, M. Plante, J. Pfisterer*
- 178 NCIC CTG IND.196: Phase I Study of Foretinib (GSK1363089) and Erlotinib in Patients with Advanced Pretreated NSCLC 607  
*N.B. Leighl, M.S. Tsao, C. Ho, F.A. Shepherd, N. Murray, J. Goffin, G. Nicholas, L. Seymour, G.D. Goss, P. Bradbury*
- 179 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors 608  
*A. Naing, M. Mita, P. Komarnitsky, A. Milner, O. von Richter, J. Ogden, S. Piha-Paul, S. Fu, E. Asatiani, R. Kurzrock*
- 180 A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Advanced Solid Tumors 609  
*P. Haluska, M.E. Menefee, E.R. Plimack, J.E. Rosenberg, D.W. Northfelt, T. LaVallee, W. Huang, X.Q. Yu, J.L. Viner, P. LoRusso*
- 181 Loss of the Tumor Suppressor Merlin as a Potential Predictive Biomarker of Clinical Activity for the Oral, Focal Adhesion Kinase (FAK) Inhibitor GSK2256098 in Pts with Recurrent Mesothelioma 610  
*J.C. Soria, R. Plummer, M. Ranson, H. Gan, H.T. Arkenau, G. Zalcman, S. Blagden, T.R.J. Evans, V. Peddareddigari, J. Mazumdar, S. Murray, D. Gibson, R.A. Fleming, K. Auger, M. Millward*
- 182 Assessment of CYP3A Inhibition, Food Effect, and Glucose/insulin Changes with Prednisone Co-administration in a Phase 1 Trial of the Oral, ATP-competitive Akt Inhibitor GDC-0068 611  
*L. Musib, N. Budha, R. Funke, V. Malhi, B.M. Liederer, M.J. Dresser, R. Meng, P. Patel, A. Cervantes, J. Tabernero*
- 183 MOSCATO: a Molecular Screening Triage Trial for Patients Enrolled in Phase I Trials 612  
*C. Massard, N. Auger, P. Vielh, L. Lacroix, V. Lazar, M. Ngocamus, M.C. Le Deley, F. Andre, T. DeBaere, J.C. Soria*
- 184 Pharmacokinetics/pharmacodynamics (PK/PD) of GSK2256098, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Advanced Solid Tumors 613  
*H. Gan, N. Nebot, J.C. Soria, H.T. Arkenau, S. Blagden, R. Plummer, M. Ranson, T.R.J. Evans, G. Zalcman, V. Peddareddigari, D. Gibson, S. Murray, J. Mazumdar, R. Fleming, K. Auger, M. Millward*

- 185 First-in-man Dose Escalation and Pharmacokinetic Study of CAP7.1, a Novel Etoposide Prodrug in Adults with Heavily Pretreated Solid Tumors 614  
*U. Keilholz, M. Knoedler, A. Schmittel, V. Kümmerlen, K. Klinghammer, L. Rohde, P. Mehlitz, C. Gehringer, S. Joel, N. Utku*
- 186 QTc Intervals as Inclusion/exclusion Criteria in Phase I Trial with Anticancer Agents: Vall d’Hebron Experience 615  
*A. Delgado Colston, M. Baños, M. Soria, A. Azaro, R. Dienstmann, G. Argiles, C. Cruz, J. Capdeville, J. Tabernero, J. Rodon*
- 187 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma 616  
*J.P. Delord, N. Houédé, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond*
- 188 Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction 617  
*J. Sarantopoulos, E.G. Chiorean, J. Stephenson, H. Burris, D. Mahalingam, A. Younger, M. Ayan-Oshodi, J. Baldwin, J.R. Infante*
- 189 Integrated Analysis of Pharmacokinetics and Exposure–Adverse Event Relationship of the Investigational Agent MLN0128 to Guide Dose and Schedule Selection for Further Clinical Investigation 618  
*C. Patel, P.J. Lipman, K. Venkatakrishnan*
- 190 Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors 619  
*A. Cervantes, C. Saura, D. Roda, R. Dienstmann, S. Rosello, J. Carles, R. Funke, J. Zhu, R. Meng, J. Tabernero*
- 191 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors 620  
*D.W. Rasco, A. Patnaik, A. Amaya, S. Gaylor, T. Moore, E. Izbicka, R. Streeper, W. Rodriguez, R. Messmann, A. Tolcher*
- 192 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors 621  
*P. ODonnell, J.W. Goldman, M.S. Gordon, K. Shih, Y.J. Choi, D. Lu, O. Kabbarah, W. Ho, I. Rooney, E.T. Lam*

### Radiation Interactive Agents

Poster board

Abstract number

- 193 Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 Signaling is Associated with Selective Activation of Autophagy 622  
*D. Soto-Pantoja, G. Gema Martin Manso, L.A. Ridnour, W. DeGraff, D.A. Wink, D.D. Roberts*
- 194 Evaluating the Potential of OXi4503 to Enhance Tumour Response to Radiation Administered in Clinically Relevant Conventional or Stereotactic Schedules 623  
*M.R. Horsman*
- 195 Radiosensitization of Glioma Cell Lines by a Novel Peptidomimetic of the Second Mitochondria-derived Activator of Caspases (SMAC) 624  
*D. Cerna, D. Carter, N. Takebe, C.N. Coleman, S. Yoo*